

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Direct oral anticoagulant therapies for atrial fibrillation: changing profiles of newly treated patients

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018180
Article Type:	Research
Date Submitted by the Author:	12-Jun-2017
Complete List of Authors:	Huiart, Laetitia; CIC 1410 Ferdynus, Cyril; CHU de la Réunion, Unité de Soutien Méthodologique; CHU Réunion, CIC INSERM 1410 Renoux, Christel; McGill University, Neurology & Neurosurgery Beaugrand, Amélie; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Lafarge, Sophie; CHU Réunion, CIC INSERM 1410 Bruneau, Léa; CHU de la Réunion, Unité de Soutien Méthodologique Suissa, Samy; McGill University, Maillard, Olivier; CHU Réunion, CIC INSERM 1410 Ranouil, Xavier; CHU de la Réunion, Service de Cardiologie
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Cardiovascular medicine, Pharmacology and therapeutics, Public health
Keywords:	Cohort, Atrial Fibrillation, anticoagulants, Vitamine K antagonist, direct oral anti-coagulants

SCHOLARONE™  
Manuscripts



1  
2  
3 **Direct oral anticoagulant therapies for atrial fibrillation: changing profiles of newly treated**  
4  
5 **patients**  
6  
7  
8

9 Laetitia Huiart (1,2,3,4), Cyril Ferdynus (1,2), Christel Renoux (5,6,7), Amélie Beaugrand (1,8),  
10  
11 Sophie Lafarge (2), Léa Bruneau (1,4), Samy Suissa (5,7), Olivier Maillard (2,4), Xavier Ranouil  
12  
13  
14 (9)  
15

16  
17  
18  
19 Names of Authors:  
20

21 1 - CHU de la Réunion, Unité de Soutien Méthodologique, Saint-Denis, France  
22

23 2 - CHU de la Réunion, INSERM, CIC 1410, Saint-Pierre, France.  
24

25 3 - Université de La Réunion, UFR Santé, Saint-Denis, France  
26

27  
28 4 - INSERM, Université d'Aix-Marseille, IRD, UMR912 "Sciences Économiques et Sociales de  
29  
30 la Santé et Traitement de l'Information Médicale" (SESSTIM), F-13006 Marseille, France.  
31

32 5 - Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish  
33  
34 General Hospital, Montréal, QC, Canada.  
35

36  
37 6 - Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.  
38

39 7 - Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, Canada  
40

41 8 - Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France  
42

43  
44 9 - CHU de la Réunion, Service de cardiologie, Saint-Denis, France  
45  
46  
47

48  
49 Corresponding author: telephone number, fax number and e-mail address  
50

- 51 • Name: Laetitia Huiart
- 52
- 53 • Institution: INSERM
- 54
- 55

- Mail: Unité de Soutien Méthodologique, CIC 1410, CHU La Réunion, Allée Topaze, 97400 Saint-Denis
- Tel and FAX numbers : +262.2.62.90.68.82 / fax: +262.2.62.90.69.21
- e- mail: laetitia.huiart@mail.mcgill.ca

For peer review only

**Abstract (300 words)***Objective*

Unlike several other national health agencies, French health authorities recommended that the newer direct oral anticoagulant (DOAC) agents only be prescribed as second choice for the treatment of newly diagnosed non-valvular atrial fibrillation (NVAF), with vitamin K antagonists (VKA) remaining the first choice. We investigated the patterns of use of DOACs versus VKA in the treatment of NVAF in France over the first five years of DOAC availability. We also identified the changes in patient characteristics of those who initiated DOAC treatment over this time period.

*Methods*

Based on the French National Health Administrative Database, we constituted a population-based cohort of all patients who were newly treated for NVAF between January 2011 and December 2015. Trends in drug use were described as the percentage of patients initiating each drug at the time of treatment initiation. A multivariate analysis using logistic regression model was performed to identify independent sociodemographic and clinical predictors of initial anticoagulant choice.

*Results*

The cohort comprised 814,446 patients who had received a new anticoagulant treatment for NVAF. The proportion of patients using DOACs as initial anticoagulant therapy reached 54% three months after the Health Ministry approved the reimbursement of dabigatran for NVAF, and 61% by the end of 2015, versus VKA use. In the multivariate analysis, we found that DOAC initiators were younger and healthier overall than VKA initiators, and this tendency was reinforced over the 2011-2014 period. DOACs were more frequently

1  
2  
3 prescribed by cardiologists in 2012 and after (adjusted-OR in 2012: 2.47; 95% Confidence  
4  
5 Interval: 2.40-2.54).

### 6 7 *Conclusion*

8  
9 Despite recommendations from health authorities, DOACs have been rapidly and massively  
10  
11 adopted as initial therapy for NVAf in France. Observational studies should account for the  
12  
13 fact that patients selected to initiate DOAC treatment are healthier overall, as failure to do  
14  
15 so may bias the risk-benefit assessment of DOACs.  
16  
17

18  
19 **Keywords (6 max)**

20  
21 Cohort, atrial fibrillation, anticoagulants, vitamin K antagonist, direct oral anticoagulants  
22

23  
24 **Tables: 2**

25  
26 **Figures: 5**

27  
28 **Supplementary material: 6 tables**  
29  
30  
31  
32  
33  
34

### 35 **Strength and limitations:**

- 36  
37 • With a source database covering 63 million inhabitants and exhaustive information  
38  
39 on anticoagulant deliveries in France, our study is the largest to report penetration of  
40  
41 DOACs on the market. This is particularly the case for apixaban, which is the most  
42  
43 recent DOAC available  
44
- 45  
46 • The administrative database used does not include clinical results; nor does it include  
47  
48 outpatients' diagnosis codes. To account for outpatients, we based our definition of  
49  
50 NVAf on drug dispensation, using the most likely treatment scheme for NVAf. We  
51  
52 conducted sensitivity analyses to ensure that our results are consistent.  
53  
54  
55

## Introduction

Non-Valvular Atrial fibrillation (NVAf) is the most common sustained cardiac arrhythmia, and its age-adjusted prevalence has been increasing over time.<sup>1,2</sup> NVAf is associated with high morbidity and mortality, as it increases the risks of stroke and systemic thromboembolic events.<sup>2</sup> In light of this, the use of an oral anticoagulant is recommended in patients with NVAf at medium or high risk of stroke.<sup>3-7</sup> For more than 50 years, vitamin K antagonists (VKA) such as warfarin were the only effective therapy available for stroke prevention in patients with NVAf.<sup>8</sup> However, the efficacy and safety of VKAs are closely related to the quality of anticoagulation, which is open to substantial inter- and intra-patient variability and requires close biological monitoring.<sup>9, 8, 10</sup>

In order to respond to physicians' and patients' expectations of more user-friendly drugs, research on new drugs has intensified over the last few years. This has prompted the development of direct oral anticoagulants (DOAC) that inhibit thrombin or factor Xa. Large randomised clinical trials (RCTs) have compared the efficacy of DOACs to that of warfarin in patients with NVAf.<sup>11,12,13</sup> A recent meta-analysis of these RCTs has shown that the frequency of strokes and/or systemic embolic events is 19% lower with DOACs than it is with warfarin. Moreover, compared with warfarin, DOACs have been shown to present similar risks of major bleeding but higher risks of gastrointestinal bleeding.<sup>14</sup> The risk-benefit ratio of DOACs nevertheless varies according to patient profile.<sup>15, 16</sup>

In France, the direct thrombin inhibitor dabigatran was the first DOAC to be approved for the primary prevention of venous thromboembolism in orthopedic surgery (in 2008) and stroke in NVAf (in 2011). Reimbursement of dabigatran for the treatment of NVAf was

1  
2  
3 approved in July 2012. Two new oral direct factor Xa inhibitors, rivaroxaban and apixaban,  
4  
5 were made available for patients with NVAF in September 2012 and January 2014,  
6  
7 respectively. Given the initial lack of specific antidotes and of data on these drugs' efficacy  
8  
9 and safety in real life, French Health Authorities recommended that VKAs remain the  
10  
11 standard therapy. They also recommended that DOACs be offered as an alternative therapy  
12  
13 only to patients with low adherence to VKAs or unstable INRs (International Normalised  
14  
15 Ratios) on VKAs.<sup>17</sup> To date, it is not clear how the expectations of clinicians and the  
16  
17 recommendations of health authorities have impacted the choice of anticoagulant for newly  
18  
19 treated patients with NVAF. Nor is it clear how patients' characteristics have influenced  
20  
21 treatment choice.  
22  
23  
24

25  
26 In view of the above, this study aimed to identify the initial oral anticoagulant therapy used  
27  
28 in a cohort of patients newly diagnosed with NVAF for the prevention of stroke and systemic  
29  
30 thromboembolism. It also sought to describe changes in the characteristics of patients who  
31  
32 initiated treatment during the first five years of DOAC availability in France.  
33  
34  
35

## 36 37 **Method**

### 38 39 *Study design and source of data*

40  
41  
42 The retrospective population-based cohort of patients with NVAF was formed from data  
43  
44 provided by the French National Health Insurance System (NHIS). The NHIS guarantees  
45  
46 universal health coverage to all segments of the population, and includes both a drug  
47  
48 delivery database and a hospital discharge database. The NHIS comprises health insurance  
49  
50 schemes for salaried workers, self-employed workers, agricultural workers and farmers, as  
51  
52 well as 12 other insurance schemes. Together, these schemes provide health insurance to  
53  
54  
55



1  
2  
3 approximately 63 million inhabitants, which corresponds to 93% of the French population.

4  
5 Detailed description of the NHIS database is provided elsewhere.<sup>18,19</sup>

6  
7 In France, drugs are available only in pharmacies, and a medical prescription is required to  
8  
9 obtain anticoagulant drugs. All reimbursement claims for prescriptions processed and filled  
10  
11 in pharmacies are submitted to the NHIS via a single electronic system. This drug delivery  
12  
13 database is linked to the hospital discharge database through a unique personal identifier  
14  
15 allocated to every individual. The second database provides medical information on all  
16  
17 patients discharged from hospitals, along with associated ICD-10 diagnosis codes (10<sup>th</sup>  
18  
19 version of International Classification of Diseases). However, no clinical diagnosis is provided  
20  
21 in this database for outpatient consultations with general practitioners and specialists.  
22  
23  
24  
25  
26  
27

### 28 *Cohort definition*

29  
30 We defined a cohort of all patients 18 years and older who were newly treated for NVAF  
31  
32 between January 1, 2011 and December 31, 2015. Cohort entry was defined by the delivery  
33  
34 of anticoagulant therapy (VKA or DOAC) combined with an antiarrhythmic agent (flecainide,  
35  
36 propafenone, amiodarone, quinidine, disopyramide or sotalol) or a rate control treatment  
37  
38 (beta-blocker, calcium channel agonists or digoxin) within a time window of +/- 30 days. The  
39  
40 date of cohort entry was the latest date of delivery of either drug, within the 30 day window.  
41  
42  
43

44 We excluded patients with less than 1 year of data available in the database before cohort  
45  
46 entry, as well as patients who had received anticoagulant treatment or had a history of  
47  
48 cardiac valvular replacement in the 12 months before inclusion. Lastly, we excluded patients  
49  
50 who had undergone lower limb orthopedic surgery within 30 days of inclusion.  
51  
52

### 53 *Exposure*

1  
2  
3 We identified patients' exposure to initial anticoagulant treatment. We compared patients  
4  
5 initiating VKA treatment—acenocoumarol, fluindione, warfarin (the 3 most commonly used  
6  
7 VKAs in France), as well as phenindione and tiocloamarol—to patients receiving any of the 3  
8  
9 DOACs available during the study period (dabigatran, rivaroxaban or apixaban).  
10

#### 11 Study covariates

12  
13  
14 The following characteristics of patients were identified in the year prior to cohort entry  
15  
16 using treatment and/or hospital discharge code: high blood pressure, coronary artery  
17  
18 disease (including myocardial infarction and ischemic heart disease), congestive heart  
19  
20 failure, diabetes, a personal history of cancer, renal failure, liver failure, dementia, a history  
21  
22 of bleeding, and history of ischemic stroke. Exposure to treatment other than  
23  
24 anticoagulants—aspirin or other nonsteroidal anti-inflammatory drugs, antiplatelet agents  
25  
26 (other than aspirin), corticosteroids—was identified in the 3 months prior to cohort entry.  
27  
28 We also determined whether initial anticoagulant therapy was prescribed by a general  
29  
30 practitioner, a cardiologist or a physician with another specialty. To estimate the risk of  
31  
32 major bleeding, we calculated a modified HAS-BLED score (hypertension, abnormal renal  
33  
34 and/or liver function, stroke/TIA, bleeding, labile international normalised ratio (INR), age  
35  
36 >65, antiplatelet/NSAID use, or alcohol abuse).<sup>20</sup> Labile INR was not included in the score  
37  
38 because it is both unavailable in the database and irrelevant for new DOAC users. Alcohol  
39  
40 abuse was determined based on the hospital discharge database. To estimate the risk of  
41  
42 stroke, we calculated the CHA2DS2-VASc2 score (congestive heart failure, hypertension, age  
43  
44 ≥75, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65–74, and  
45  
46 sex).<sup>21</sup>  
47  
48  
49  
50  
51  
52

#### 53 *Data analysis*

1  
2  
3 Descriptive statistics were computed for continuous data (mean, +/- standard deviation (sd)  
4 or median and range) and for categorical data (frequency and proportion). Trends in drugs  
5 use were described as the number of new patients treated each month and as the  
6 percentage of each anticoagulant prescribed at the time of treatment initiation.  
7  
8  
9

10  
11 Patients' characteristics were described according to initial anticoagulant therapy received.

12  
13  
14 In bivariate comparisons, the characteristics of patients and prescribers were compared  
15 according to the type of anticoagulant, using a t-test for continuous variables, and a chi-  
16 square test for categorical variables. To identify independent predictors of initial  
17 anticoagulant choice, we performed a multivariate analysis using a logistic regression model  
18 stratified by calendar year of anticoagulant initiation. The model included all the variables  
19 that were associated with a p-value <0.20 in the bivariate comparisons. These variables were  
20 selected using a backward selection approach. Further, we defined 2 other cohorts for the  
21 sensitivity analyses: 1) one cohort was defined more restrictively: it included patients who  
22 were newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate  
23 control treatment other than beta-blocker agents within a time window of +/- 30 days; 2)  
24 the other cohort was defined according to broader inclusion criteria: it comprised all  
25 patients newly treated with an anticoagulant, regardless of other potential concomitant  
26 therapies.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Statistical significance was set at 0.05. All p-values were two sided.

45  
46 All statistical analyses were performed using SAS version 9.4 (SAS institute, Cary Inc).  
47  
48  
49  
50

## 51 **Results**

52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In France, 1,772,399 individuals were delivered a prescription for either a VKA or a DOAC  
4  
5 between January 1, 2011 and December 31, 2015 (Figure 1). Out of this sample, we  
6  
7 identified 872,970 individuals who received a new prescription for an anticoagulant (VKA or  
8  
9 DOAC) combined with a prescription for an antiarrhythmic agent or a rate control treatment  
10  
11 within a time window of +/- 30 days. Ultimately, the cohort comprised 814,446 patients  
12  
13 newly treated for NVAf: 506,821 subjects initiated VKA, 94,468 dabigatran, 169,524  
14  
15 rivorixaban, and 43,633 apixaban.  
16  
17

18  
19 Figure 2 illustrates the percentages of patients initiating one of the different anticoagulant  
20  
21 treatments over the study period. A sharp rise in DOAC use was observed starting in mid-  
22  
23 2012. As of October 2012, DOACs were used more frequently than VKAs as initial  
24  
25 anticoagulant therapy, representing 54% of all anticoagulant prescriptions (30% for  
26  
27 dabigatran and 24% for rivaroxaban). In the last quarter of 2015, this percentage reached  
28  
29 61% (4% for dabigatran, 34% for rivaroxaban, and 24% for apixaban). The proportion of  
30  
31 patients initiating dabigatran began to decline 6 months after reimbursement was approved,  
32  
33 and even more so after October 2013. Rivaroxaban use increased sharply as early as  
34  
35 September 2012. This drug was the most frequently initiated DOAC in early 2013, and it  
36  
37 remained so until December 2015, when it was surpassed by apixaban (26% vs 28% in  
38  
39 December 2015).  
40  
41  
42  
43

44  
45 The mean age of newly treated patients was 74.9 (sd: 11.7), and 50.2% of patients were  
46  
47 male (table 1). Most subjects were treated for high blood pressure (94.4%), and 22.2% were  
48  
49 treated for diabetes. Patients who received DOACs had less comorbidities and were on  
50  
51 average younger than those who were prescribed VKAs (73.8 years (sd: 11.5) versus 75.6  
52  
53 years (sd: 11.9)  $p < 0.0001$ ). General practitioners prescribed VKAs (67.5%) more frequently  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 than DOACs (32.5%) as initial anticoagulant therapy, whereas cardiologist favored DOACs  
4  
5 (51.2%). Patients receiving apixaban were older than those receiving other DOACs (76.2 vs.  
6  
7 72.9 for rivaroxaban and 74.1 for dabigatran). They also had more comorbidities, such as  
8  
9 high blood pressure and heart or renal failure (table 2). Patients with lower HAS-BLED or  
10  
11 lower CHA2DS2-VASc scores were more likely to initiate DOACs (figure 3).  
12  
13

14 The characteristics and associated treatments of DOAC initiators as compared with VKA  
15  
16 initiators changed over the 5-year period (Figure 4 and 5). Older subjects ( $\geq 75$  years) were  
17  
18 less likely to initiate DOAC treatment than VKA treatment. The adjusted OR decreased from  
19  
20 0.86 in 2011 (95% Confidence Interval (95%CI): 0.80 to 0.92) to 0.62 in 2014 (95%CI: 0.61 to  
21  
22 0.64). Overall, patients with comorbidities—especially renal failure—were less likely to  
23  
24 receive DOAC treatment, and this negative association was reinforced over the study period  
25  
26 (adjusted OR for 2014: 0.22; 95%CI: 0.21-0.23). The negative association was not reinforced  
27  
28 in 2015, likely due the fact that a larger proportion of patients received apixaban. Patients  
29  
30 with a history of bleeding prior to cohort entry were less likely to receive DOAC treatment  
31  
32 (adjusted OR for 2015: 0.56; 95%CI: 0.53-0.59). Since 2012, cardiologists have been strongly  
33  
34 associated with initial prescription of DOACs, after accounting the patients' characteristics.  
35  
36  
37 The sensitivity analyses conducted for the 2 other cohorts provided similar results: a rapid  
38  
39 increase in the use of DOAC over time, and a healthier profile of patients receiving DOACs  
40  
41 compared with those receiving VKAs (supplementary material cohort 1 and cohort 2).  
42  
43  
44  
45

## 46 Discussion

47  
48  
49 Less than 6 months after reimbursement was approved, DOACs became the most frequently  
50  
51 prescribed initial anticoagulant therapy for NVAf in France. Starting in the third quarter of  
52  
53 2012, DOACs were delivered to over 60% of all patients newly treated for NVAf. Dabigatran,  
54  
55

1  
2  
3 rivaroxaban and, in late 2015, apixaban were used one after the other as the most frequent  
4  
5 initial DOAC therapy for NVAF. The proportion of dabigatran initiators declined largely after  
6  
7 2013. DOAC initiators were younger and healthier than VKA users, and this tendency was  
8  
9 reinforced over time. The use of DOACs varied over time depending on the availability of  
10  
11 new drugs and on the national recommendations and safety warnings in place.  
12  
13

14 National trends in anticoagulant sales volumes have also been reported in other countries,  
15  
16 revealing an important upsurge in DOAC use.<sup>22, 23</sup> Most studies based on registries or cohorts  
17  
18 of patients with NVAF have reported dabigatran use rates ranging from 5% to 25%, which is  
19  
20 lower than what we found in our study.<sup>24-27</sup> However, in the US, Desai *et al.* have reported  
21  
22 an increase in DOAC use for the 2010-2013 period which is similar to the one we observed,  
23  
24 with a peak of 62% of patients initiating DOAC treatment among a cohort of anticoagulant  
25  
26 initiators.<sup>28</sup> This convergence of results is surprising given the differences in populations,  
27  
28 health systems, drug coverage, and, most importantly, clinical recommendations on the use  
29  
30 of DOACs for the treatment of NVAF between countries. Thus, in France, health authorities  
31  
32 do not recommend DOACs as initial anticoagulant therapy, unless the patient has poor  
33  
34 adherence to VKAs or unless biological monitoring of VKA treatment is difficult.<sup>17</sup>  
35  
36  
37  
38  
39  
40  
41

42 The sharp rise in DOAC use in France was observed as of mid-2012, shortly after the NHIS  
43  
44 approved the reimbursement of dabigatran. Specifically, dabigatran was authorised as an  
45  
46 anticoagulant for the treatment of NVAF in August 2011; reimbursement of treatment was  
47  
48 pre-approved in February 2012, and it was fully approved in July 2012. Starting in November  
49  
50 2012, DOACs were used more frequently than VKAs as initial anticoagulant therapy. The  
51  
52 reimbursement of rivaroxaban was fully approved in September 2012, and the drug was  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 used more frequently than dabigatran as initial anticoagulant therapy as of January 2013.  
4  
5 This rapid uptake of DOACs in the drug market may be explained by the fact that alternatives  
6  
7 to VKAs had long been expected. Indeed, a recent study indicates that DOACs were  
8  
9 preferred to VKAs by more than a third of surveyed physicians.<sup>29</sup> The speed of adoption of  
10  
11 DOACs is similar to that described for other new drugs, which usually reaches a plateau 6 to  
12  
13 12 months after they are launched.<sup>30</sup> This speed varies according to the specialty of the  
14  
15 prescriber, and specialists are generally more prompt to adopt new drugs<sup>30</sup>—as was the case  
16  
17 in our study. Nevertheless, some studies have reported no impact of physician specialty on  
18  
19 the prescription of DOACs.<sup>24,27</sup> The differences we observed between the prescriptions of  
20  
21 general practitioners (GP) and those of cardiologists may reflect the gap between national  
22  
23 and European clinical guidelines. Indeed, French Health Authorities recommend VKAs as  
24  
25 initial anticoagulant therapy, whereas the European Society of Cardiology favors DOACs.<sup>3</sup>  
26  
27 GPs in the rest of Europe have taken a more cautious approach towards DOACs. This is  
28  
29 especially the case in the treatment of elderly populations, most likely because there  
30  
31 remains substantial uncertainty concerning the effectiveness and safety of DOACs in  
32  
33 unselected elderly patients with NVAf.<sup>31</sup>  
34  
35  
36  
37  
38  
39  
40  
41

42 Our results indicate that the characteristics of patients who initiated treatment with DOACs  
43  
44 rather than VKAs evolved over the first few years of drug commercialisation. In the first year,  
45  
46 we observed a similar selection process as that described by Desai *et al.*, with healthier  
47  
48 patients using DOACs more frequently than VKAs as initial therapy.<sup>28</sup> This tendency was  
49  
50 reinforced as DOAC initiators became healthier over time. The prescription of DOACs to  
51  
52 healthier patients is an issue that needs to be addressed, as these molecules may offer  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 higher-risk patients greater benefits than VKAs,<sup>32</sup> but also because their cost effectiveness  
4  
5 depends on the severity of patients' condition.<sup>33</sup> Observational studies that aim to evaluate  
6  
7 the risks and benefits associated with DOACs as well as cost effectiveness studies should  
8  
9 carefully account for the fact that patients selected to initiate DOAC treatment are healthier  
10  
11 overall, as well as for the selection of patients on the different types of DOACs.<sup>34</sup> Failure to  
12  
13 do so may lead to underestimating the potential risks associated with DOACs in real life  
14  
15 studies.  
16

17  
18 The fact that DOAC initiation is less frequent among patients with comorbidities may result  
19  
20 from a warning issued by different health agencies in France.<sup>35</sup> This tendency seems to be  
21  
22 linked to the diminishing use of dabigatran observed at the end of 2013, when the French  
23  
24 medicine safety agency released warnings on bleeding risks associated with the drug.<sup>36,37,38</sup>  
25  
26 At the time, French health authorities informed health professionals that DOACs are not  
27  
28 recommended as initial therapy for NVAf, unless the patient has poor adherence to VKAs or  
29  
30 unless biological monitoring of VKA treatment is difficult. However, while these  
31  
32 recommendations were followed by a temporary decrease in DOAC use, a few months later  
33  
34 DOACs were once again the most frequently prescribed anticoagulants for patients newly  
35  
36 treated for NVAf.  
37  
38  
39  
40  
41  
42  
43

44 Our study has several strengths. The source database covers 63 million inhabitants and over  
45  
46 93% of the French population, which means that our findings are independent of individual  
47  
48 health coverage. Moreover, we had access to exhaustive information on anticoagulant  
49  
50 delivery because these treatments are delivered on prescription alone. As a result, our study  
51  
52 is the largest to report penetration of DOACs on the market (particularly in the case of  
53  
54  
55



1  
2  
3 apixaban, which is the most recent DOAC available) and to describe variations in the  
4  
5 characteristics of patients over time.  
6  
7

8  
9 Nevertheless, some limitations must also be acknowledged. The NHIS administrative  
10  
11 database does not include clinical or biological results; nor does it include outpatients'  
12  
13 diagnosis codes. To capture outpatient diagnosis of AF, we based our definition of NVAF on  
14  
15 drug dispensation, using the most likely treatment scheme for NVAF. Insofar as the results of  
16  
17 our sensitivity analyses are consistent, we can be confident that our findings are not  
18  
19 sensitive to the definition of NVAF. Moreover, 69% of patients who were hospitalised during  
20  
21 follow-up had a diagnostic code of NVAF in the hospital discharge database (data not  
22  
23 shown). Another limitation of our study is due to the 2015 data that may be partially  
24  
25 incomplete. Indeed, for patients who do not have their NHIS card and attend a pharmacy  
26  
27 that is not their regular pharmacy - a paper reimbursement form may be issued. The data  
28  
29 are then recorded when the paper form is sent to the NHIS and integrated later in the  
30  
31 database. When the 2015 data were made available, paper claims were likely to have not all  
32  
33 been included. However, this changes the total number of users but not the proportion of  
34  
35 users of the different drugs.  
36  
37  
38  
39  
40  
41  
42  
43

44 The rapid and massive adoption of DOACs as initial therapy for NVAF could potentially  
45  
46 challenge the French health care system because of the important increase in costs  
47  
48 associated with these new drugs (in the US, these costs accounted for more than 90% of  
49  
50 insurer spending on anticoagulants in 2014<sup>28</sup>) and because of the uncertainty concerning the  
51  
52 cost-effectiveness of these drugs in real life. Future observational studies should carefully  
53  
54  
55

1  
2  
3 account for the fact that patients selected to initiate DOAC treatment are healthier overall,  
4  
5 and that this tendency is reinforced over the first few years of drug commercialization.  
6  
7 Failure to do so may bias the risk-benefit assessment of DOACs.  
8  
9

#### 10 11 12 *Contributor ship statement*

13  
14 LH, XR, CF designed the study. All authors have contributed substantially to the  
15  
16 interpretation of results. In addition: LH and AB drafted the article; - CF conducted the  
17  
18 statistical analysis; CF, CR, SL, LB, SS, OM, XR provided critical revision of the manuscript for  
19  
20 important intellectual content. All authors had full access to all of the data (including  
21  
22 statistical reports and tables) in the study and can take responsibility for the integrity of the  
23  
24 data and the accuracy of the data analysis. All authors approved the version to be published.  
25  
26  
27  
28  
29

#### 30 31 *Competing interests*

32  
33 Pr. Suissa has participated in advisory board meetings and received research grants from  
34  
35 Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb and Novartis. These activities are  
36  
37 conducted outside this submitted study.  
38

39 All other co-authors have no conflict of interest.  
40  
41  
42  
43

#### 44 45 *Funding*

46  
47 This research was supported by a 2012 research grant from the Agence Nationale de  
48  
49 Sécurité du Médicament (ANSM).  
50  
51  
52

#### 53 54 *Data sharing statement*

1  
2  
3 No additional data are available directly from the authors. The datasource of the study is the  
4  
5 French National Health Insurance. Data are available from the Caisse National de l'Assurance  
6  
7 Maladie des Travailleurs Salariés (CNAMTS) for academic research.  
8  
9

### 10 11 12 *Ethics approval*

13  
14 The study was approved by the French National Institute of Data, and by the National  
15  
16 Commission for Data Protection and Liberties (CNIL-France: authorization number:  
17  
18 1637014).  
19  
20

### 21 22 23 *Acknowledgements*

24  
25 We thank the Caisse National de l'Assurance Maladie des Travailleurs Salariés (CNAMTS) and  
26  
27 the Institut des Données de Santé (IDS) for their assistance in obtaining the study database.

28  
29 We personally thank Ms. Valérie EDEL from the IDS, as well as Mr. Laurent DUCHET and Mr.  
30  
31 Medhi GABBAS from the department in charge of the SNIIRAM DATA at CNAM-TS.

32  
33 We are indebted to Arianne Dorval for proofreading the English manuscript. C Renoux is the  
34  
35 recipient of a Chercheur-Boursier Award from the Fonds de la recherche du Québec - santé  
36  
37 (FRQ-S). S Suissa is the recipient of the James McGill Chair.  
38  
39  
40  
41  
42  
43  
44  
45

### 46 **References**

- 47  
48  
49 1. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk  
50 for development of atrial fibrillation: the Framingham Heart Study. *Circulation*. 2004; **110**(9):  
51 1042-6.  
52 2. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of  
53 an evolving epidemic in the 21st century. *Int J Cardiol*. 2013; **167**(5): 1807-24.  
54  
55

3. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.* 2012; **14**(10): 1385-413.
4. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology.* 2014; **64**(21): e1-76.
5. Jones C, Pollit V, Fitzmaurice D, Cowan C. The management of atrial fibrillation: summary of updated NICE guidance. *BMJ.* 2014; **348**: g3655.
6. Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *Can J Cardiol.* 2014; **30**(10): 1114-30.
7. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012; **141**(2 Suppl): e531S-75S.
8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med.* 2007; **146**(12): 857-67.
9. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. *Thromb Haemost.* 2013; **109**(4): 569-79.
10. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. *Ann Intern Med.* 1996; **124**(11): 970-9.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2009; **361**(12): 1139-51.
12. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med.* 2011; **365**(10): 883-91.
13. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2011; **365**(11): 981-92.
14. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet.* 2014; **383**(9921): 955-62.
15. Potpara TS, Lip GY. Novel oral anticoagulants in non-valvular atrial fibrillation. *Best Pract Res Clin Haematol.* 2013; **26**(2): 115-29.
16. Shields AM, Lip GY. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. *J Intern Med.* 2015; **278**(1): 1-18.

17. Haute Autorité de Santé. Fibrillation auriculaire non valvulaire - Quelle place pour les anticoagulants oraux non antivitamine K: apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®). Bon usage du médicament 2013 [cited; Available from: [http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-07/fs\\_bum\\_naco\\_v5.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-07/fs_bum_naco_v5.pdf)]
18. Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! *Pharmacoepidemiol Drug Saf.* 2010; **19**(3): 256-65.
19. Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. *Fundam Clin Pharmacol.* 2016; **30**(6): 616-24.
20. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest.* 2010; **138**(5): 1093-100.
21. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest.* 2010; **137**(2): 263-72.
22. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. *Circ Cardiovasc Qual Outcomes.* 2012; **5**(5): 615-21.
23. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. *Am J Med.* 2015; **128**(12): 1300-5 e2.
24. Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. *J Am Heart Assoc.* 2013; **2**(6): e000535.
25. Sorensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbol EL, Hvidtfeldt MW, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. *BMJ Open.* 2013; **3**(5).
26. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, et al. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. *Am J Med.* 2014; **127**(6): 519-29 e1.
27. Mochalina N, Joud A, Carlsson M, Sandberg ME, Sjalander A, Juhlin T, et al. Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study. *Thrombosis research.* 2016; **140**: 94-9.
28. Desai NR, Krumme AA, Schneeweiss S, Shrank WH, Brill G, Pezalla EJ, et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. *Am J Med.* 2014; **127**(11): 1075-82 e1.
29. Larsen TB, Potpara T, Dagres N, Proclemer A, Sciarrafia E, Blomstrom-Lundqvist C. Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.* 2015; **17**(5): 819-24.
30. Garjon FJ, Azparren A, Vergara I, Azaola B, Loayssa JR. Adoption of new drugs by physicians: a survival analysis. *BMC Health Serv Res.* 2012; **12**: 56.

- 1  
2  
3 31. Opstelten W, van den Donk M, Kuijpers T, Burgers J. New oral anticoagulants for  
4 nonvalvular atrial fibrillation in the elderly: Limited applicability in primary care. *Eur J Gen*  
5 *Pract.* 2015; **21**(2): 145-9.
- 6 32. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. *JAMA.*  
7 2015; **313**(19): 1950-62.
- 8 33. Wisloff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran,  
9 rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. *Pharmacoeconomics.*  
10 2014; **32**(6): 601-12.
- 11 34. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative  
12 effectiveness of newly marketed medications: methodological challenges and implications  
13 for drug development. *Clinical pharmacology and therapeutics.* 2011; **90**(6): 777-90.
- 14 35. Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA. Contraindicated  
15 medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear  
16 Doctor' letters. *Pharmacoepidemiol Drug Saf.* 2001; **10**(3): 211-8.
- 17 36. Agence Nationale de Sécurité du Médicament et des produits de santé. Nouveaux  
18 anticoagulants oraux Eliquis (apixaban), Pradaxa (dabigatran), Xarelto (rivaroxaban) : mise en  
19 garde sur les facteurs de risques hémorragiques - Lettre aux professionnels de santé. 2013  
20 [cited; Available from:  
21  
22 37. Haute Autorité de Santé. Les anticoagulants oraux antivitamine K restent la référence  
23 dans la fibrillation auriculaire non valvulaire - Communiqué de presse. 2013.
- 24 38. Haute Autorité de Santé. Point sur l'utilisation des nouveaux anticoagulants oraux -  
25 Communiqué de Presse. 2013 [cited; Available from: [http://www.has-](http://www.has-sante.fr/portail/jcms/c_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux)  
26 [sante.fr/portail/jcms/c\\_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-](http://www.has-sante.fr/portail/jcms/c_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux)  
27 [oraux](http://www.has-sante.fr/portail/jcms/c_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux)  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60







Figure 1 – Flow-chart describing cohort constitution




**Figure 2 – Time trends in the prescription of anticoagulants in newly treated patients with Atrial Fibrillation between 2011 and 2015 in France (n = 814,446)**

(VKA: vitamin K antagonist, DOAC: direct oral anticoagulant)






**Figure 3 – HAS-BLED and CHA2DS2-VASc scores associated with DOAC vs VKA initiation according to year of therapy initiation. Crude Odds Ratio and 95% confidence interval**



**Figure 4 – Determinants associated with DOAC vs VKA initiation according to year of therapy initiation in the multivariate analyses. Adjusted OR and 95% confidence interval**

*Other variables in the logistic regression model: sex, ischemic heart disease, heart failure, diabetes, cancer, liver failure, dementia, treatment at cohort entry - Aspirin, NSAID, Antiplatelet agents and corticosteroids. (Results on figure 4 and 5 are issued from the same statistical model)*



**Figure 5 – Treatments at cohort entry associated with DOAC vs VKA initiation according to year of therapy initiation in the multivariate analyses. Adjusted OR and 95% confidence interval**

*Other variables in the logistic regression model: age, sex, blood pressure, ischemic heart disease, heart failure, diabetes, cancer, renal failure, liver failure, dementia, history of ischemic stroke, history of bleeding, medical specialty of first prescriber of anticoagulant. (Results on figure 4 and 5 are issued from the same statistical model)*

**Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015)**

	VKA* N = 506,821	DOACs† N = 307,625
<b>Demographic characteristics</b>		
Mean age (sd)‡	75.6 (11.9)	73.8 (11.5)
Male	49.3%	51.7%
<b>Clinical characteristics§</b>		
High blood pressure	95.4%	92.7%
Ischemic heart disease	28.6%	18.1%
Heart failure	27.8%	17.2%
Diabetes	23.6%	19.6%
Cancer	16.5%	12.9%
Renal failure	10.9%	2.6%
Liver failure	1.7%	0.7%
Dementia	5.2%	3.0%
History Ischemic stroke	9.6%	7.1%
History of bleeding	6.3%	3.1%
HAS-BLED score, mean (sd)	2.7 (0.9)	2.4 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> -VASC <sub>2</sub> score, mean (sd)	3.9 (1.5)	3.4 (1.4)
<b>Other treatment at cohort entry  </b>		
Aspirin	45.8%	42.0%
Nonsteroidal anti-inflammatory drugs	13.7%	16.3%
Antiplatelet Agents (other than Aspirin)	15.8%	11.5%
Corticosteroids	14.0%	12.5%
<b>Prescriber of first anticoagulant</b>		
General Practitioner	64.4%	51.2%
<i>Among General Practitioners</i>	67.5%	32.5%
Cardiologist	22.2%	38.3%
<i>Among Cardiologists</i>	48.8%	51.2%
Other specialist	4.8%	4.6%
Unknown	8.6%	6.0%

\* Vitamin K agonist; † Direct oral anticoagulants; ‡ sd: standard deviation; § defined in the 12 months prior to cohort entry; || defined in the 3 months prior to cohort entry

**Table 2 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation in the Sub-Group of Patients Receiving a Direct Oral Anticoagulant (2011-2015)**

	Dabigatran N = 94,468	Rivaroxaban N = 169,524	Apixaban N = 43,633
<b>Demographic characteristics</b>			
Mean age (sd) <sup>†</sup>	74.1 (11.3)	73.0 (11.5)	76.2 (11.1)
Male	52.3%	52.0%	49.5%
<b>Clinical characteristics<sup>‡</sup></b>			
High blood pressure	92.1%	92.5%	94.7%
Ischemic heart disease	19.7%	17.4%	17.6%
Heart failure	18.9%	15.2%	21.5%
Diabetes	19.9%	19.7%	20.8%
Cancer	14.0%	12.8%	11.1%
Renal failure	2.3%	2.4%	4.1%
Liver failure	0.7%	0.7%	0.6%
Dementia	3.1%	2.9%	3.3%
History of ischemic stroke	8.4%	6.0%	9.0%
History of bleeding	2.9%	3.1%	3.9%
HAS-BLED score, mean (sd)	2.4 (0.9)	2.4 (0.9)	2.5 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> -VASC <sub>2</sub> , mean (sd)	3.5 (1.5)	3.3 (1.4)	3.7 (1.4)
<b>Other treatments at cohort entry<sup>§</sup></b>			
Aspirin	43.3%	40.9%	43.6%
Nonsteroidal anti-inflammatory drugs	16.6%	16.9%	13.0%
Antiplatelet Agents (other than Aspirin)	12.1%	10.9%	12.4%
Corticosteroids	12.2%	12.7%	12.1%
<b>Prescriber of first anticoagulant</b>			
General Practitioner	50.2%	51.9%	50.4%
Cardiologist	38.9%	38.0%	37.9%
Other specialist	4.4%	4.7%	4.6%
Unknown	6.5%	5.4%	7.1%

\* Direct oral anticoagulants, † Standard deviation, ‡ defined in the 12 months prior to cohort entry, § defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015)**

	VKA* N = 289,430	DOACs† N = 199,016
<b>Demographic characteristics</b>		
Mean age (sd) <sup>§</sup>	76.1 (11.2)	73.7 (11.3)
Male	49.8%	52.5%
<b>Clinical characteristics<sup>  </sup></b>		
High blood pressure	91.9%	88.7%
Ischemic heart disease	26.3%	16.6%
Heart failure	34.4%	21.6%
Diabetes	21.9%	18.6%
Cancer	16.1%	13.0%
Renal failure	9.7%	2.4%
Liver failure	1.3%	0.7%
Dementia	4.6%	2.7%
History Ischemic stroke	8.5%	6.2%
History of bleeding	5.5%	2.9%
HAS-BLED score, mean (sd)	2.6 (0.9)	2.4 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> score, mean (sd)	3.9 (1.5)	3.4 (1.5)
<b>Other treatment at cohort entry<sup>¶</sup></b>		
Aspirin	45.9%	42.2%
Nonsteroidal anti-inflammatory drugs	13.8%	15.9%
Antiplatelet Agents (other than Aspirin)	14.4%	10.9%
Corticosteroids	13.9%	12.8%
<b>Prescriber of first anticoagulant</b>		
General Practitioner	59.7%	46.7%
<i>Among general practitioners</i>	65.0%	35.0%
Cardiologist	27.7%	43.8%
<i>Among cardiologists</i>	47.9%	52.1%
Other specialist	4.2%	3.8%
Unknown	8.4%	5.6%

\* Vitamin K agonist; † Direct oral anticoagulants; ‡, p value comparing VKA vs DOACs; § sd: standard deviation; || defined in the 12 months prior to cohort entry; ¶ defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 2 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation in the Sub-Group of Patients Receiving a Direct Oral Anticoagulant (2011-2015)**

	<b>Dabigatran</b> <b>N = 65,851</b>	<b>Rivaroxaban</b> <b>N = 104,936</b>	<b>Apixaban</b> <b>N = 28,229</b>
<b>Demographic characteristics</b>			
Mean age (sd) <sup>†</sup>	73.7 (11.4)	73.0 (11.3)	76.0 (11.0)
Male	52.3%	53.4%	49.6%
<b>Clinical characteristics<sup>‡</sup></b>			
High blood pressure	88.7%	87.8%	91.8%
Ischemic heart disease	17.9%	15.8%	17.0%
Heart failure	22.8%	19.9%	25.2%
Diabetes	18.6%	18.3%	20.0%
Cancer	14.0%	12.8%	11.3%
Renal failure	2.1%	2.2%	3.8%
Liver failure	0.7%	0.6%	0.6%
Dementia	2.8%	2.6%	2.9%
History of ischemic stroke	7.2%	5.4%	7.1%
History of bleeding	2.7%	2.7%	3.6%
HAS-BLED score, mean (sd)	2.4 (0.9)	2.3 (0.9)	2.5 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> -VASC <sub>2</sub> , mean (sd)	3.4 (1.5)	3.2 (1.5)	3.6 (1.4)
<b>Other treatments at cohort entry<sup>§</sup></b>			
Aspirin	43.0%	41.4%	43.2%
Nonsteroidal anti-inflammatory drugs	16.6%	16.1%	13.2%
Antiplatelet Agents (other than Aspirin)	11.3%	10.4%	12.1%
Corticosteroids	12.8%	12.8%	12.6%
<b>Prescriber of first anticoagulant</b>			
General Practitioner	47.0%	46.3%	47.5%
Cardiologist	43.1%	44.9%	41.7%
Other specialist	3.7%	3.8%	4.1%
Unknown	6.2%	5.0%	6.7%

\* Direct oral anticoagulants, † Standard deviation, ‡ defined in the 12 months prior to cohort entry, § defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 3 – Multivariate analysis of the determinants associated with DOAC initiation according to year of therapy initiation**

Characteristics at treatment initiation	2011 N = 101,817		2012 N = 110,571		2013 N = 103,594		2014 N = 94,180		2015 N = 78,284	
	Adjusted OR	CI 95%*	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%
<b>Demographic characteristics</b>										
Age										
< 65 years	0.89	0.78 – 1.01	0.93	0.88 – 0.97	1.02	0.98 – 1.06	1.15	1.10 – 1.21	1.08	1.03 – 1.14
65 –74 years	1.0		1.0		1.0		1.0		1.0	
>= 75 years	1.15	1.04 – 1.27	0.98	0.94 – 1.01	0.69	0.67 – 0.71	0.59	0.57 – 0.61	0.65	0.63 – 0.68
Sex (Male)	0.86	0.79 – 0.94	0.97	0.94 – 1.01	1.09	1.06 – 1.13	1.10	1.06 – 1.13	1.08	1.05 – 1.12
<b>Clinical characteristics<sup>†</sup></b>										
High blood pressure	0.87	0.76 – 1.00	0.82	0.78 – 0.86	0.79	0.75 – 0.83	0.78	0.74 – 0.82	0.79	0.74 – 0.84
Ischemic heart disease	0.88	0.79 – 0.97	0.83	0.80 – 0.86	0.76	0.74 – 0.79	0.74	0.72 – 0.77	0.76	0.72 – 0.79
Heart failure	0.60	0.55 – 0.67	0.70	0.68 – 0.72	0.61	0.59 – 0.63	0.59	0.57 – 0.61	0.63	0.60 – 0.65
Diabetes	0.88	0.79 – 0.98	0.89	0.86 – 0.93	0.88	0.85 – 0.91	0.93	0.89 – 0.96	0.92	0.89 – 0.96
Cancer	0.98	0.88 – 1.10	0.96	0.92 – 1.00	0.85	0.81 – 0.88	0.85	0.81 – 0.88	0.84	0.80 – 0.89
Renal failure	0.50	0.39 – 0.63	0.34	0.31 – 0.36	0.23	0.22 – 0.25	0.22	0.20 – 0.23	0.24	0.23 – 0.26
Liver failure	0.59	0.33 – 1.05	0.74	0.63 – 0.88	0.59	0.52 – 0.68	0.58	0.50 – 0.66	0.49	0.41 – 0.58
Dementia	0.96	0.77 – 1.19	0.84	0.77 – 0.92	0.75	0.70 – 0.80	0.81	0.76 – 0.88	0.74	0.68 – 0.81
History of Ischemic Stroke	1.01	0.87 – 1.16	0.99	0.94 – 1.05	0.88	0.84 – 0.93	0.88	0.84 – 0.93	0.92	0.86 – 0.98
History of bleeding	1.28	1.06 – 1.55	0.70	0.64 – 0.76	0.52	0.48 – 0.55	0.52	0.49 – 0.56	0.57	0.53 – 0.61
<b>Prescriber of first anticoagulant</b>										
General Practitioner	1.0		1.0		1.0		1.0		1.0	
Cardiologist	1.30	1.19 – 1.42	2.33	2.25 – 2.41	2.63	2.55 – 2.71	2.57	2.49 – 2.65	2.46	2.37 – 0.56
Other specialists/Unknown	1.72	1.52 – 1.93	1.03	0.97 – 1.08	1.00	0.96 – 1.05	1.03	0.98 – 1.07	1.03	0.98 – 1.08
<b>Other treatments at cohort entry<sup>‡</sup></b>										
Aspirin	1.28	1.18 – 1.42	1.16	1.12 – 1.19	0.98	0.85 – 1.00	0.93	0.90 – 0.95	0.87	0.84 – 0.90
NSAID	1.37	1.24 – 1.52	1.16	1.11 – 1.21	1.18	1.13 – 1.22	1.21	1.17 – 1.27	1.20	1.14 – 1.26
Antiplatelet Agents	1.30	1.15 – 1.46	1.06	1.01 – 1.11	0.85	0.82 – 0.89	0.73	0.70 – 0.76	0.78	0.74 – 0.82
Corticosteroids	0.90	0.79 – 1.02	0.96	0.92 – 1.00	0.93	0.89 – 0.96	0.98	0.94 – 1.02	0.92	0.88 – 0.96
<b>Time of anticoagulant initiation</b>										
1 <sup>st</sup> term of the year	1.0		1.0		1.0		1.0		1.0	
2 <sup>nd</sup> term of the year	1.13	0.96 – 1.32	3.17	2.98 – 3.37	1.00	0.96 – 1.04	1.08	1.04 – 1.13	1.11	1.06 – 1.15
3 <sup>rd</sup> term of the year	2.05	1.77 – 2.37	9.37	8.84 – 9.94	0.93	0.89 – 0.96	1.09	1.05 – 1.14	1.17	1.11 – 1.22
4 <sup>th</sup> term of the year	4.71	4.14 – 5.36	31.06	29.34 – 32.88	0.54	0.52 – 0.56	1.35	1.30 – 1.40	1.39	1.33 – 1.45

\* 95% Confidence interval; † defined in the 12 months prior to cohort entry; ‡ defined in the 3 months prior to cohort entry



**Supplemental material – Sensitivity analysis – Cohort 2** - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant therapies

**Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015).**

	VKA* N = 952,565	DOACs <sup>†</sup> N = 661,089
<b>Demographic characteristics</b>		
Mean age (sd <sup>§</sup> )	71.7 (15.3)	69.5 (13.8)
Male	48.4%	49.2%
<b>Clinical characteristics<sup>  </sup></b>		
High blood pressure	78.5%	71.3%
Ischemic heart disease	21.0%	11.9%
Heart failure	18.6%	8.8%
Diabetes	19.9%	15.7%
Cancer	16.7%	11.6%
Renal failure	9.3%	1.9%
Liver failure	1.6%	0.6%
Dementia	5.5%	2.4%
History Ischemic stroke	8.6%	5.0%
History of bleeding	6.8%	3.6%
HAS-BLED score, mean (sd)	2.3 (1.1)	2.0 (1.1)
CHA <sub>2</sub> DS <sub>2</sub> -VASc <sub>2</sub> score, mean (sd)	3.3 (1.7)	2.8 (1.6)
<b>Other treatment at cohort entry<sup>¶</sup></b>		
Aspirin	35.8%	28.9%
Nonsteroidal anti-inflammatory drugs	17.1%	28.4%
Antiplatelet Agents (other than Aspirin)	11.7%	7.4%
Corticosteroids	15.1%	12.7%
<b>Prescriber of first anticoagulant</b>		
General Practitioner	70.7%	54.1%
<i>Among General Practitioners</i>	64.7%	35.3%
Cardiologist	15.6%	21.7%
<i>Among Cardiologists</i>	50.0%	50.0%
Other specialist	5.8%	18.2%
Unknown	7.9%	6.0%

\* Vitamin K agonist; † Direct oral anticoagulants; ‡, p value comparing VKA vs DOACs; § sd: standard deviation; || defined in the 12 months prior to cohort entry; ¶ defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 2** - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant therapies

**Table 2 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation in the Sub-Group of Patients Receiving a Direct Oral Anticoagulant (2011-2015) AC**

	Dabigatran N = 174,423	Rivaroxaban N = 419,780	Apixaban N = 66,886
<b>Demographic characteristics</b>			
Mean age (sd) <sup>†</sup>	71.5 (12.5)	67.8 (14.3)	74.5 (11.8)
Male	49.6%	49.0%	49.4%
<b>Clinical characteristics<sup>‡</sup></b>			
High blood pressure	76.9%	66.9%	84.4%
Ischemic heart disease	14.8%	10.4%	14.0%
Heart failure	11.0%	6.9%	15.3%
Diabetes	16.9%	14.6%	18.8%
Cancer	12.7%	11.3%	10.8%
Renal failure	1.9%	1.7%	3.7%
Liver failure	0.6%	0.6%	0.6%
Dementia	2.6%	2.2%	3.1%
History of ischemic stroke	6.5%	3.9%	8.4%
History of bleeding	3.5%	3.6%	4.0%
HAS-BLED score, mean (sd)	2.2 (1.0)	1.9 (1.1)	2.4 (1.0)
CHA <sub>2</sub> DS <sub>2</sub> -VASC <sub>2</sub> , mean (sd)	3.0 (1.6)	2.6 (1.6)	3.4 (1.5)
<b>Other treatments at cohort entry<sup>§</sup></b>			
Aspirin	32.8%	25.9%	37.6%
Nonsteroidal anti-inflammatory drugs	28.3%	29.8%	19.4%
Antiplatelet Agents (other than Aspirin)	8.7%	6.4%	10.1%
Corticosteroids	11.9%	13.1%	11.7%
<b>Prescriber of first anticoagulant</b>			
General Practitioner	48.2%	56.9%	51.4%
Cardiologist	24.1%	19.6%	29.2%
Other specialist	20.9%	18.0%	12.0%
Unknown	6.8%	5.5%	7.4%

\* Direct oral anticoagulants, † Standard deviation, ‡ defined in the 12 months prior to cohort entry, § defined in the 3 months prior to cohort entry

1 **Supplemental material – Sensitivity analysis – Cohort 2** - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant  
 2 therapies

3 **Table 3 – Multivariate analysis of the determinants associated with DOAC initiation according to year of therapy initiation.**

Characteristics at treatment initiation	2011 N = 319*,372		2012 N = 353,242		2013 N = 327,150		2014 N = 311,352		2015 N =275,538	
	Adjusted OR	CI 95%*	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%
<b>Demographic characteristics</b>										
Age										
< 65 years	0.57	0.56 – 0.59	0.63	0.62 – 0.64	0.74	0.72 – 0.76	0.81	0.79 – 0.82	0.81	0.79 – 0.83
65 –74 years	1.0		1.0		1.0		1.0		1.0	
>= 75 years	0.56	0.55 – 0.58	0.76	0.75 – 0.78	0.69	0.68 – 0.70	0.59	0.58 – 0.60	0.66	0.65 – 0.67
Sex (Male)	0.86	0.84 – 0.88	0.98	0.96 – 0.99	1.09	1.07 – 1.11	1.08	1.06 – 1.09	1.06	1.04 – 1.08
<b>Clinical characteristics<sup>†</sup></b>										
High blood pressure	0.76	0.74 – 0.78	0.90	0.88 – 0.92	0.95	0.93 – 0.97	0.89	0.87 – 0.91	0.87	0.85 – 0.89
Ischemic heart disease	0.78	0.76 – 0.81	0.81	0.79 – 0.83	0.76	0.75 – 0.78	0.74	0.72 – 0.76	0.77	0.75 – 0.80
Heart failure	0.15	0.14 – 0.16	0.56	0.54 – 0.57	0.63	0.62 – 0.64	0.58	0.56 – 0.59	0.64	0.63 – 0.66
Diabetes	0.89	0.86 – 0.92	0.90	0.88 – 0.92	0.89	0.87 – 0.91	0.89	0.87 – 0.91	0.91	0.89 – 0.93
Cancer	0.71	0.69 – 0.73	0.81	0.79 – 0.83	0.75	0.73 – 0.76	0.73	0.72 – 0.75	0.70	0.68 – 0.72
Renal failure	0.29	0.27 – 0.32	0.30	0.29 – 0.32	0.23	0.22 – 0.24	0.22	0.21 – 0.23	0.26	0.25 – 0.27
Liver failure	0.50	0.44 – 0.57	0.50	0.46 – 0.55	0.47	0.43 – 0.50	0.43	0.40 – 0.47	0.40	0.37 – 0.44
Dementia	0.29	0.26 – 0.31	0.56	0.54 – 0.59	0.61	0.59 – 0.63	0.60	0.58 – 0.63	0.63	0.60 – 0.66
History of Ischemic Stroke	0.24	0.22 – 0.26	0.66	0.64 – 0.68	0.76	0.74 – 0.78	0.74	0.72 – 0.76	0.81	0.78 – 0.84
History of bleeding	1.00	0.95 – 1.05	0.70	0.68 – 0.73	0.54	0.52 – 0.56	0.53	0.51 – 0.55	0.54	0.52 – 0.56
<b>Prescriber of first anticoagulant</b>										
General Practitioner	1.0		1.0		1.0		1.0		1.0	
Cardiologist	0.26	0.25 – 0.28	1.91	1.87 – 1.95	2.86	2.80 – 2.92	2.78	2.72 – 2.84	2.67	2.60 – 2.73
Other specialists/Unknown	7.01	6.85 – 7.18	3.76	3.69 – 3.84	1.83	1.79 – 1.87	1.79	1.75 – 1.82	1.55	1.51 – 1.58
<b>Other treatments at cohort entry<sup>‡</sup></b>										
Aspirin	0.71	0.69 – 0.73	1.00	0.98 – 1.02	0.98	0.96 – 1.00	0.91	0.90 – 0.93	0.87	0.85 – 0.88
NSAID	2.77	2.71 – 2.83	1.93	1.90 – 1.97	1.57	1.54 – 1.60	1.56	1.53 – 1.59	1.57	1.53 – 1.60
Antiplatelet Agents	0.64	0.61 – 0.68	0.94	0.91 – 0.97	0.83	0.81 – 0.85	0.75	0.72 – 0.77	0.76	0.73 – 0.78
Corticosteroids	0.60	0.58 – 0.62	0.70	0.68 – 0.72	0.79	0.77 – 0.80	0.84	0.82 – 0.86	0.87	0.85 – 0.89
<b>Time of anticoagulant initiation</b>										
1 <sup>st</sup> term of the year	1.0		1.0		1.0		1.0		1.0	
2 <sup>nd</sup> term of the year	1.02	0.99 – 1.05	1.35	1.32 – 1.38	1.05	1.03 – 1.07	1.12	1.10 – 1.14	1.10	1.08 – 1.13
3 <sup>rd</sup> term of the year	0.81	0.78 – 0.83	2.22	2.17 – 2.28	0.96	0.94 – 0.98	1.09	1.07 – 1.12	1.12	1.10 – 1.15
4 <sup>th</sup> term of the year	1.32	1.29 – 1.37	5.92	5.79 – 6.05	0.69	0.68 – 0.70	1.38	1.35 – 1.41	1.31	1.28 – 1.34

\* 95% Confidence interval; † defined in the 12 months prior to cohort entry; ‡ defined in the 3 months prior to cohort entry

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	Database study – NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	Administrative database study – no missing variable

		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Only variable at cohort entry were used
		(e) Describe any sensitivity analyses	9
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	11 and figure 1
		(c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	NA – admin database study – no missing variables
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Variables only at cohort entry
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Figure 4-5
		(b) Report category boundaries when continuous variables were categorized	Table 2
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary table
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on	14

1  
2  
3  
4 which the present article is based  
5

6 \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

7 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE  
8 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
9 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only

# BMJ Open

## Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in the French Health Insurance databases

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018180.R1
Article Type:	Research
Date Submitted by the Author:	13-Oct-2017
Complete List of Authors:	Huiart, Laetitia; CIC 1410 Ferdynus, Cyril; CHU de la Réunion, Unité de Soutien Méthodologique; CHU Réunion, CIC INSERM 1410 Renoux, Christel; McGill University, Neurology & Neurosurgery Beaugrand, Amélie; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Lafarge, Sophie; CHU Réunion, CIC INSERM 1410 Bruneau, Léa; CHU de la Réunion, Unité de Soutien Méthodologique Suissa, Samy; McGill University, Maillard, Olivier; CHU Réunion, CIC INSERM 1410 Ranouil, Xavier; CHU de la Réunion, Service de Cardiologie
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Cardiovascular medicine, Pharmacology and therapeutics, Public health
Keywords:	Cohort, Atrial Fibrillation, anticoagulants, Vitamine K antagonist, direct oral anti-coagulants

SCHOLARONE™  
Manuscripts

1  
2  
3 **Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in the French**  
4  
5 **Health Insurance databases**  
6  
7  
8

9 Laetitia Huiart (1,2,3,4), Cyril Ferdynus (1,2), Christel Renoux (5,6,7), Amélie Beaugrand (1,8),  
10 Sophie Lafarge (2), Léa Bruneau (1,4), Samy Suissa (5,7), Olivier Maillard (2,4), Xavier Ranouil  
11  
12  
13  
14 (9)  
15

16  
17  
18  
19 Names of Authors:  
20

21 1 - CHU de la Réunion, Unité de Soutien Méthodologique, Saint-Denis, France  
22

23 2 - CHU de la Réunion, INSERM, CIC 1410, Saint-Pierre, France.  
24

25 3 - Université de La Réunion, UFR Santé, Saint-Denis, France  
26

27  
28 4 - INSERM, Université d'Aix-Marseille, IRD, UMR912 "Sciences Économiques et Sociales de  
29 la Santé et Traitement de l'Information Médicale" (SESSTIM), F-13006 Marseille, France.  
30

31  
32 5 - Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish  
33 General Hospital, Montréal, QC, Canada.  
34

35  
36 6 - Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.  
37

38  
39 7 - Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, Canada  
40

41  
42 8 - Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France  
43

44 9 - CHU de la Réunion, Service de cardiologie, Saint-Denis, France  
45  
46  
47

48  
49 Corresponding author: telephone number, fax number and e-mail address  
50

- 51 • Name: Laetitia Huiart
- 52
- 53 • Institution: INSERM
- 54
- 55



- Mail: Unité de Soutien Méthodologique, CIC 1410, CHU La Réunion, Allée Topaze, 97400 Saint-Denis
- Tel and FAX numbers : +262.2.62.90.68.82 / fax: +262.2.62.90.69.21
- e- mail: laetitia.huiart@mail.mcgill.ca

For peer review only

**Abstract (300 words)***Objective*

Unlike several other national health agencies, French health authorities recommended that the newer direct oral anticoagulant (DOAC) agents only be prescribed as second choice for the treatment of newly diagnosed non-valvular atrial fibrillation (NVAF), with vitamin K antagonists (VKA) remaining the first choice. We investigated the patterns of use of DOACs versus VKA in the treatment of NVAF in France over the first five years of DOAC availability. We also identified the changes in patient characteristics of those who initiated DOAC treatment over this time period.

*Methods*

Based on the French National Health Administrative Database, we constituted a population-based cohort of all patients who were newly treated for NVAF between January 2011 and December 2015. Trends in drug use were described as the percentage of patients initiating each drug at the time of treatment initiation. A multivariate analysis using logistic regression model was performed to identify independent sociodemographic and clinical predictors of initial anticoagulant choice.

*Results*

The cohort comprised 814,446 patients who had received a new anticoagulant treatment for NVAF. The proportion of patients using DOACs as initial anticoagulant therapy reached 54% three months after the Health Ministry approved the reimbursement of dabigatran for NVAF, and 61% by the end of 2015, versus VKA use. In the multivariate analysis, we found that DOAC initiators were younger and healthier overall than VKA initiators, and this tendency was reinforced over the 2011-2014 period. DOACs were more frequently

1  
2  
3 prescribed by cardiologists in 2012 and after (adjusted-OR in 2012: 2.47; 95% Confidence  
4  
5 Interval: 2.40-2.54).

### 6 7 *Conclusion*

8  
9 Despite recommendations from health authorities, DOACs have been rapidly and massively  
10  
11 adopted as initial therapy for NVAf in France. Observational studies should account for the  
12  
13 fact that patients selected to initiate DOAC treatment are healthier overall, as failure to do  
14  
15 so may bias the risk-benefit assessment of DOACs.  
16  
17

18  
19 **Keywords (6 max)**

20  
21 Cohort, atrial fibrillation, anticoagulants, vitamin K antagonist, direct oral anticoagulants  
22

23  
24 **Tables: 2**

25  
26 **Figures: 3**

27  
28 **Supplementary material: 6 tables**  
29  
30

### 31 32 33 34 35 **Strength and limitations:**

- 36  
37
- 38 • With a source database covering 66 million inhabitants and exhaustive information  
39 on anticoagulant deliveries in France, our study is the largest to report penetration of  
40 DOACs on the market. This is particularly the case for apixaban, which was the most  
41 recent DOAC available at the time of the study  
42  
43
  - 44 • The administrative database used does not include clinical results; nor does it include  
45 outpatients' diagnosis codes. To account for outpatients, we based our definition of  
46 NVAf on drug dispensation, using the most likely treatment scheme for NVAf. We  
47  
48 conducted sensitivity analyses to ensure that our results are consistent.  
49  
50  
51  
52  
53  
54  
55

## Introduction

Non-Valvular Atrial fibrillation (NVAf) is the most common sustained cardiac arrhythmia, and its age-adjusted prevalence has been increasing over time.<sup>1,2</sup> NVAf is associated with high morbidity and mortality, as it increases the risks of stroke and systemic thromboembolic events.<sup>2</sup> In light of this, the use of an oral anticoagulant is recommended in patients with NVAf at medium or high risk of stroke.<sup>3-7</sup> For more than 50 years, vitamin K antagonists (VKA) such as warfarin were the only effective therapy available for stroke prevention in patients with NVAf.<sup>8</sup> However, the efficacy and safety of VKAs are closely related to the quality of anticoagulation, which is open to substantial inter- and intra-patient variability and requires close biological monitoring.<sup>9, 8,10</sup>

In order to respond to physicians' and patients' expectations of more user-friendly drugs, research on new drugs has intensified over the last few years. This has prompted the development of direct oral anticoagulants (DOAC) that inhibit thrombin or factor Xa. Large randomised clinical trials (RCTs) have compared the efficacy of DOACs to that of warfarin in patients with NVAf.<sup>11, 12,13</sup> A recent meta-analysis of these RCTs has shown that the frequency of strokes and/or systemic embolic events is 19% lower with DOACs than it is with warfarin. Moreover, compared with warfarin, DOACs have been shown to present similar risks of major bleeding but higher risks of gastrointestinal bleeding.<sup>14</sup> The benefit-risk ratio of DOACs nevertheless varies across individual agents, and also according to patient profile.<sup>15,16</sup>

In France, the direct thrombin inhibitor dabigatran was the first DOAC to be approved for the primary prevention of venous thromboembolism in orthopedic surgery (in 2008) and stroke in NVAf (in 2011). Reimbursement of dabigatran for the treatment of NVAf was

1  
2  
3 approved in July 2012. Two new oral direct factor Xa inhibitors, rivaroxaban and apixaban,  
4  
5 were made available for patients with NVAf in September 2012 and January 2014,  
6  
7 respectively. Given the initial lack of specific antidotes and of data on these drugs' efficacy  
8  
9 and safety in real life, French Health Authorities recommended that VKAs remain the  
10  
11 standard therapy. They also recommended that DOACs be offered as an alternative therapy  
12  
13 only to patients with low adherence to VKAs or unstable INRs (International Normalised  
14  
15 Ratios) on VKAs.<sup>17</sup> To date, it is not clear how the expectations of clinicians and the  
16  
17 recommendations of health authorities have impacted the choice of anticoagulant for newly  
18  
19 treated patients with NVAf. Nor is it clear how patients' characteristics have influenced  
20  
21 treatment choice.  
22  
23

24  
25 In view of the above, we conducted a study in the French National health administrative  
26  
27 database. This study based on claims data, aimed to identify the initial oral anticoagulant  
28  
29 therapy used in a cohort of patients newly diagnosed with NVAf for the prevention of stroke  
30  
31 and systemic thromboembolism. It also sought to describe changes in the characteristics of  
32  
33 patients who initiated treatment during the first five years of DOAC availability in France.  
34  
35  
36  
37  
38

## 39 **Method**

### 40 *Study design and source of data*

41  
42 The retrospective population-based cohort of patients with NVAf was formed from data  
43  
44 provided by the French National Health Insurance System (NHIS).<sup>18</sup> The NHIS guarantees  
45  
46 universal health coverage to all segments of the population, and includes both a drug  
47  
48 delivery database and a hospital discharge database. The NHIS comprises health insurance  
49  
50 schemes for salaried workers, self-employed workers, agricultural workers and farmers, as  
51  
52  
53  
54  
55

1  
2  
3 well as 12 other insurance schemes. Together, these schemes provide health insurance to  
4  
5 approximately 66 million inhabitants, which corresponds to approximately 99% of the  
6  
7 French population.<sup>19</sup> Detailed description of the NHIS database is provided elsewhere.<sup>20,21</sup>  
8

9  
10 In France, drugs are available only in pharmacies, and a medical prescription is required to  
11  
12 obtain anticoagulant drugs. All reimbursement claims for prescriptions processed and filled  
13  
14 in pharmacies are submitted to the NHIS via a single electronic system. This drug delivery  
15  
16 database is linked to the hospital discharge database through a unique personal identifier  
17  
18 allocated to every individual. The second database provides medical information on all  
19  
20 patients discharged from hospitals, along with associated ICD-10 diagnosis codes (10<sup>th</sup>  
21  
22 version of International Classification of Diseases). However, no clinical diagnosis is provided  
23  
24 in this database for consultations by health professionals in an ambulatory care setting.  
25  
26  
27  
28  
29

### 30 *Cohort definition*

31  
32 We defined a cohort of all patients 18 years and older who were newly treated for NVAf  
33  
34 between January 1, 2011 and December 31, 2015. Cohort entry was defined by the delivery  
35  
36 of anticoagulant therapy (VKA or DOAC) combined with either an antiarrhythmic agent  
37  
38 (flecainide, propafenone, amiodarone, quinidine, disopyramide or sotalol) or a rate control  
39  
40 treatment (beta-blocker, calcium channel blockers - verapamil and diltiazem -, or digoxin)  
41  
42 within a time window of +/- 30 days. The date of cohort entry was the latest date of delivery  
43  
44 of either drug, within the 30 day window. We excluded patients with less than 1 year of data  
45  
46 available in the database before cohort entry, as well as patients who had received  
47  
48 anticoagulant treatment or had a history of cardiac valvular replacement in the 12 months  
49  
50 before inclusion. Therefore, the anticoagulant therapy received at cohort inclusion  
51  
52  
53  
54  
55

1  
2  
3 corresponded to a new anticoagulant therapy. Lastly, we excluded patients who had  
4  
5 undergone lower limb orthopedic surgery within +/- 30 days of inclusion.  
6

#### 7 Exposure

8  
9 We identified patients' exposure to initial anticoagulant treatment. We compared patients  
10  
11 initiating VKA treatment—acenocoumarol, fluindione, warfarin (the 3 most commonly used  
12  
13 VKAs in France)—to patients receiving any of the 3 DOACs available during the study period  
14  
15 (dabigatran, rivaroxaban or apixaban).  
16  
17

#### 18 Study covariates

19  
20 The following characteristics of patients were identified in the year prior to cohort entry  
21  
22 using treatment and/or hospital discharge code (supplementary table): high blood pressure,  
23  
24 coronary artery disease (including myocardial infarction and ischemic heart disease),  
25  
26 congestive heart failure, diabetes, a personal history of cancer, renal failure, liver failure,  
27  
28 dementia, a history of bleeding, and history of ischemic stroke. Exposure to treatment other  
29  
30 than anticoagulants—aspirin or other nonsteroidal anti-inflammatory drugs, antiplatelet  
31  
32 agents (other than aspirin), corticosteroids—was identified in the 3 months prior to cohort  
33  
34 entry. We also determined whether initial anticoagulant therapy was prescribed by a general  
35  
36 practitioner, a cardiologist or a physician with another specialty. To estimate the risk of  
37  
38 major bleeding, we calculated a modified HAS-BLED score (hypertension, abnormal renal  
39  
40 and/or liver function, stroke/TIA, bleeding, labile international normalised ratio (INR), age  
41  
42 >65, antiplatelet/NSAID use, or alcohol abuse).<sup>22</sup> Labile INR was not included in the score  
43  
44 because it is unavailable in the database. Alcohol abuse was determined based on the  
45  
46 hospital discharge database. To estimate the risk of stroke, we calculated the CHA2DS2-  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 VASc2 score (congestive heart failure, hypertension, age  $\geq 75$ , diabetes mellitus,  
4 stroke/transient ischemic attack, vascular disease, age 65–74, and sex).<sup>23</sup>  
5  
6

### 7 *Data analysis*

8  
9  
10 Descriptive statistics were computed for continuous data (mean, +/- standard deviation (SD)  
11 or median and range) and for categorical data (frequency and proportion). Trends in drugs  
12 use were described as the number of new patients treated each month and as the  
13 percentage of each anticoagulant prescribed at the time of treatment initiation.  
14  
15

16  
17  
18 Patients' characteristics were described according to initial anticoagulant therapy received.

19  
20 In bivariate comparisons, the characteristics of patients and prescribers were compared  
21 according to the type of anticoagulant, using a t-test for continuous variables, and a chi-  
22 square test for categorical variables. To identify independent predictors of initial  
23 anticoagulant choice, we performed a multivariate analysis using 5 logistic regression  
24 models, one for each calendar year of anticoagulant initiation. The model included all the  
25 variables that were associated with a p-value  $< 0.20$  in the bivariate comparisons. These  
26 variables were selected using a backward selection approach. Further, we defined 2 other  
27 cohorts for the sensitivity analyses: 1) one cohort was defined more restrictively: it included  
28 patients who were newly treated with an anticoagulant combined with an antiarrhythmic  
29 agent or a rate control treatment other than beta-blocker agents within a time window of  
30 +/- 30 days; 2) the other cohort was defined according to broader inclusion criteria: it  
31 comprised all patients newly treated with an anticoagulant, regardless of other potential  
32 concomitant therapies.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 To assess the impact of timeline events on the uptake process (i.e. market authorization of  
52 each drug, reimbursement approval/downgrade and security warnings from national health  
53  
54



1  
2  
3 agency), we fitted a segmented regression model, adjusted on: 1) drug coded into four  
4 categories (VKA, dabigatran, rivaroxaban and apixaban), 2) time (linear and square terms)  
5 and 3) each timeline event. A timeline event was coded as a dichotomous variable valued 0  
6 before the event and 1 after. All these covariates were included in a primary model, then a  
7 backward selection procedure was applied to select covariates associated at a significant  
8 level ( $p < 0.05$ ). To evaluate the trends and the impact of timeline events on each drug, we  
9 entered an interaction term for each drug and other covariates (time and timeline events).  
10  
11 Statistical significance was set at 0.05. All p-values were two sided.  
12  
13

14  
15 All statistical analyses were performed using SAS version 9.4 (SAS institute, Cary Inc).  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

## 26 **Results**

27  
28 In France, 1,772,399 individuals were delivered a prescription for either a VKA or a DOAC  
29 between January 1, 2011 and December 31, 2015 (Figure 1). Out of this sample, we  
30 identified 872,970 individuals who received a new prescription for an anticoagulant (VKA or  
31 DOAC) combined with a prescription for an antiarrhythmic agent or a rate control treatment  
32 within a time window of +/- 30 days. Ultimately, the cohort comprised 814,446 patients  
33 newly treated for NVAf: 506,821 subjects initiated VKA, 94,468 dabigatran, 169,524  
34 rivaroxaban, and 43,633 apixaban.  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Figure 2 illustrates the percentages of patients initiating one of the different anticoagulant  
45 treatments over the study period. A sharp rise in DOAC use was observed starting in mid-  
46 2012. As of October 2012, DOACs were used more frequently than VKAs as initial  
47 anticoagulant therapy, representing 54% of all anticoagulant prescriptions (30% for  
48 dabigatran and 24% for rivaroxaban). In the last quarter of 2015, this percentage reached  
49  
50  
51  
52  
53  
54  
55

1  
2  
3 61% (4% for dabigatran, 34% for rivaroxaban, and 24% for apixaban). The proportion of  
4  
5 patients initiating dabigatran began to decline 6 months after reimbursement was approved,  
6  
7 and even more so after October 2013. Rivaroxaban use increased sharply as early as  
8  
9 September 2012. This drug was the most frequently initiated DOAC in early 2013, and it  
10  
11 remained so until December 2015, when it was surpassed by apixaban (26% vs 28% in  
12  
13 December 2015).

14  
15  
16 Figure 2 illustrates the percentages of patients initiating one of the different anticoagulant  
17  
18 treatments over the study period. The segmented regression model identified 5 significant  
19  
20 changepoints. The two first changepoints (line a and b in figure 2) corresponded to a sharp  
21  
22 rise in DOAC initiation in July 2012 and in September 2012, corresponding respectively to  
23  
24 dabigatran and rivaroxaban reimbursement approval time. As of October 2012, DOACs were  
25  
26 used more frequently than VKAs as initial anticoagulant therapy, representing 54% of all  
27  
28 anticoagulant prescriptions (30% for dabigatran and 24% for rivaroxaban). The third  
29  
30 changepoint identified was in September 2013 (ligne d, Figure 2) with a significant decrease  
31  
32 in the use of DOACs at the time security warnings were issued by the French health  
33  
34 authorities. From January 2014 (4<sup>th</sup> change point – line c on figure 2), DOACs initiation  
35  
36 increased again, corresponding to the time point where apixaban received reimbursement  
37  
38 approval. A final significant changepoint (line e) was identified in September 2015 and was  
39  
40 linked to a reduction in dabigatran reimbursement. In December 2015, apixaban was the  
41  
42 most prescribed DOAC (28% versus 26% for rivaroxaban).  
43  
44  
45  
46  
47  
48  
49  
50

51 The mean age of newly treated patients was 74.9 (SD: 11.7), and 50.2% of patients were  
52  
53 male (table 1). Most subjects were treated for high blood pressure (94.4%), and 22.2% were  
54  
55

1  
2  
3 treated for diabetes. Patients who received DOACs had less comorbidities and were on  
4  
5 average younger than those who were prescribed VKAs (73.8 years (SD: 11.5) versus 75.6  
6  
7 years (SD: 11.9)  $p < 0.0001$ ). General practitioners prescribed VKAs (67.5%) more frequently  
8  
9 than DOACs (32.5%) as initial anticoagulant therapy, whereas cardiologist favored DOACs  
10  
11 (51.2%). Patients receiving apixaban were older than those receiving other DOACs (76.2 vs.  
12  
13 72.9 for rivaroxaban and 74.1 for dabigatran). They also had more comorbidities, such as  
14  
15 high blood pressure and heart or renal failure (table 1). Patients with lower HAS-BLED or  
16  
17 lower CHA2DS2-VASc scores were more likely to initiate DOACs (figure 3).  
18  
19

20  
21 The characteristics and associated treatments of DOAC initiators as compared with VKA  
22  
23 initiators changed over the 5-year period (table 2). Older subjects ( $\geq 75$  years) were less  
24  
25 likely to initiate DOAC treatment than VKA treatment. The adjusted OR decreased from 0.86  
26  
27 in 2011 (95% Confidence Interval (95%CI): 0.80 to 0.92) to 0.62 in 2014 (95%CI: 0.61 to 0.64).  
28  
29 Overall, patients with comorbidities—especially renal failure—were less likely to receive  
30  
31 DOAC treatment, and this negative association was reinforced over the study period  
32  
33 (adjusted OR for 2014: 0.22; 95%CI: 0.21-0.23). The negative association was not reinforced  
34  
35 in 2015, likely due the fact that a larger proportion of patients received apixaban. However,  
36  
37 because apixaban was only available at the end of the study period, further data are needed  
38  
39 to confirm this hypothesis. Patients with a history of bleeding prior to cohort entry were less  
40  
41 likely to receive DOAC treatment (adjusted OR for 2015: 0.56; 95%CI: 0.53-0.59). Since 2012,  
42  
43 cardiologists have been strongly associated with initial prescription of DOACs, after  
44  
45 accounting the patients' characteristics.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 The sensitivity analyses conducted for the 2 other cohorts provided similar results: a rapid  
4  
5 increase in the use of DOAC over time, and a healthier profile of patients receiving DOACs  
6  
7 compared with those receiving VKAs (supplementary material cohort 1 and cohort 2).  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015)**

	VKA* N = 506,821	Dabigatran N = 94,468	Rivaroxaban N = 169,524	Apixaban N = 43,633
<b>Demographic characteristics</b>				
Mean age (sd) <sup>†</sup>	75.6 (11.9)	74.1 (11.3)	73.0 (11.5)	76.2 (11.1)
Male	49.3%	52.3%	52.0%	49.5%
<b>Clinical characteristics<sup>‡</sup></b>				
High blood pressure	95.4%	92.1%	92.5%	94.7%
Ischemic heart disease	28.6%	19.7%	17.4%	17.6%
Heart failure	27.8%	18.9%	15.2%	21.5%
Diabetes	23.6%	19.9%	19.7%	20.8%
Cancer	16.5%	14.0%	12.8%	11.1%
Renal failure	10.9%	2.3%	2.4%	4.1%
Liver failure	1.7%	0.7%	0.7%	0.6%
Dementia	5.2%	3.1%	2.9%	3.3%
History of ischemic stroke	9.6%	8.4%	6.0%	9.0%
History of bleeding	6.3%	2.9%	3.1%	3.9%
HAS-BLED score, mean (sd)	2.7 (0.9)	2.4 (0.9)	2.4 (0.9)	2.5 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> , mean (sd)	3.9 (1.5)	3.5 (1.5)	3.3 (1.4)	3.7 (1.4)
<b>Other treatments at cohort entry<sup>§</sup></b>				
Aspirin	45.8%	43.3%	40.9%	43.6%
Nonsteroidal anti-inflammatory drugs	13.7%	16.6%	16.9%	13.0%
Antiplatelet Agents (other than Aspirin)	15.8%	12.1%	10.9%	12.4%
Corticosteroids	14.0%	12.2%	12.7%	12.1%
<b>Prescriber of first anticoagulant</b>				
General Practitioner	64.4%	50.2%	51.9%	50.4%
Cardiologist	22.2%	38.9%	38.0%	37.9%
Other specialist	4.8%	4.4%	4.7%	4.6%
Unknown	8.6%	6.5%	5.4%	7.1%

\* Vitamin K agonist; † Direct oral anticoagulants; ‡ sd: standard deviation; § defined in the 12 months prior to cohort entry; || defined in the 3 months prior to cohort entry

**Table 2 – Multivariate analysis of the determinants associated with DOAC initiation according to year of therapy initiation.**

Characteristics at treatment initiation	2011 N = 159,903		2012 N = 177,131		2013 N = 170,431		2014 N = 162,674		2015 N = 144,307	
	Adjusted OR	CI 95%*	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%
Demographic characteristics										
Age										
< 65 years	0.88	0.81 – 0.96	0.82	0.79 – 0.86	0.87	0.84 – 0.90	0.99	0.95 – 1.02	0.94	0.91 – 0.98
65 –74 years	1.0		1.0		1.0		1.0		1.0	
>= 75 years	0.86	0.80 – 0.92	0.98	0.95 – 1.01	0.74	0.72 – 0.76	0.62	0.61 – 0.64	0.68	0.66 – 0.70
Sex (Male)	0.73	0.69 – 0.77	1.01	0.99 – 1.04	1.15	1.12 – 1.17	1.13	1.11 – 1.16	1.11	1.08 – 1.13
Clinical characteristics <sup>†</sup>										
High blood pressure	1.29	1.13 – 1.46	0.74	0.71 – 0.78	0.61	0.58 – 0.64	0.63	0.60 – 0.66	0.62	0.59 – 0.66
Ischemic heart disease	0.89	0.84 – 0.96	0.80	0.78 – 0.83	0.74	0.72 – 0.76	0.70	0.69 – 0.72	0.75	0.73 – 0.77
Heart failure	0.43	0.40 – 0.47	0.73	0.71 – 0.76	0.68	0.66 – 0.69	0.64	0.62 – 0.65	0.69	0.66 – 0.70
Diabetes	0.89	0.83 – 0.96	0.91	0.88 – 0.94	0.89	0.86 – 0.91	0.90	0.88 – 0.92	0.91	0.89 – 0.94
Cancer	0.93	0.86 – 1.01	0.92	0.89 – 0.95	0.82	0.80 – 0.85	0.81	0.79 – 0.83	0.80	0.77 – 0.83
Renal failure	0.45	0.38 – 0.53	0.32	0.30 – 0.35	0.23	0.22 – 0.25	0.22	0.21 – 0.23	0.25	0.24 – 0.27
Liver failure	0.58	0.41 – 0.80	0.58	0.51 – 0.66	0.48	0.44 – 0.53	0.41	0.38 – 0.46	0.40	0.35 – 0.44
Dementia	0.72	0.61 – 0.85	0.79	0.74 – 0.84	0.73	0.69 – 0.77	0.74	0.70 – 0.78	0.72	0.68 – 0.76
History of Ischemic Stroke	0.70	0.63 – 0.78	0.95	0.91 – 1.00	0.91	0.88 – 0.95	0.88	0.85 – 0.91	0.92	0.89 – 0.96
History of bleeding	1.35	1.19 – 1.52	0.68	0.64 – 0.72	0.55	0.52 – 0.58	0.53	0.50 – 0.56	0.56	0.53 – 0.59
Prescriber of first anticoagulant										
General Practitioner	1.0		1.0		1.0		1.0		1.0	
Cardiologist	0.86	0.81 – 0.93	2.47	2.40 – 2.54	2.86	2.79 – 2.93	2.73	2.67 – 2.80	2.57	2.49 – 2.64
Other specialists/Unknown	2.53	2.36 – 2.71	1.15	1.10 – 1.19	1.00	0.96 – 1.03	1.04	1.00 – 1.07	1.03	0.99 – 1.06
Other treatments at cohort entry <sup>‡</sup>										
Aspirin	1.04	0.98 – 1.10	1.13	1.10 – 1.16	0.99	0.97 – 1.01	0.93	0.91 – 0.95	0.87	0.85 – 0.89
NSAID	1.90	1.78 – 2.02	1.17	1.13 – 1.21	1.19	1.16 – 1.22	1.21	1.18 – 1.25	1.24	1.20 – 1.28
Antiplatelet Agents	1.03	0.94 – 1.12	1.03	0.99 – 1.07	0.81	0.79 – 0.84	0.72	0.70 – 0.75	0.74	0.71 – 0.77
Corticosteroids	0.76	0.69 – 0.83	0.87	0.84 – 0.94	0.89	0.86 – 0.91	0.93	0.90 – 0.96	0.93	0.90 – 0.96
Time of anticoagulant initiation										
1 <sup>st</sup> term of the year	1.0		1.0		1.0		1.0		1.0	
2 <sup>nd</sup> term of the year	1.12	1.02 – 1.23	2.85	2.72 – 2.99	1.01	0.98 – 1.04	1.10	1.07 – 1.14	1.13	1.09 – 1.16
3 <sup>rd</sup> term of the year	1.40	1.28 – 1.53	7.53	7.19 – 7.88	0.94	0.91 – 0.97	1.13	1.09 – 1.16	1.19	1.15 – 1.23
4 <sup>th</sup> term of the year	2.75	2.53 – 2.94	22.52	21.55 – 23.54	0.58	0.56 – 0.59	1.38	1.34 – 1.42	1.40	1.36 – 1.44

\* 95% Confidence interval; † defined in the 12 months prior to cohort entry; ‡ defined in the 3 months prior to cohort entry

## Discussion

Less than 6 months after reimbursement was approved, DOACs became the most frequently prescribed initial anticoagulant therapy for NVAF in France. Starting in the third quarter of 2012, DOACs were delivered to over 60% of all patients newly treated for NVAF. Dabigatran, rivaroxaban and, in late 2015, apixaban were used one after the other as the most frequent initial DOAC therapy for NVAF. The proportion of dabigatran initiators declined largely after 2013. DOAC initiators were younger and healthier than VKA users, and this tendency was reinforced over time. The use of DOACs varied over time depending on the availability of new drugs and on the national recommendations and safety warnings in place.

National trends in anticoagulant sales volumes have also been reported in other countries, revealing an important upsurge in DOAC use.<sup>24-26</sup> Most studies based on registries or cohorts of patients with NVAF have reported dabigatran use rates ranging from 5% to 25%, which is lower than what we found in our study.<sup>27-30</sup> However, in the US, Desai *et al.* have reported an increase in DOAC use for the 2010-2013 period which is similar to the one we observed, with a peak of 62% of patients initiating DOAC treatment among a cohort of anticoagulant initiators.<sup>31</sup> These common trends in results observed are surprising given the differences in populations, health systems, drug coverage, and, most importantly, clinical recommendations on the use of DOACs for the treatment of NVAF between countries. Indeed, in France, health authorities do not recommend DOACs as initial anticoagulant therapy, unless the patient has poor adherence to VKAs or unless biological monitoring of VKA treatment is difficult.<sup>17</sup> However, physicians are still free to opt for any of the available treatment and their personal beliefs on efficacy and safety influences their choices.

1  
2  
3  
4  
5 The sharp rise in DOAC use in France was observed as of mid-2012, shortly after the NHIS  
6 approved the reimbursement of dabigatran. Specifically, dabigatran was authorised as an  
7 anticoagulant for the treatment of NVAF in August 2011; reimbursement of treatment was  
8 pre-approved in February 2012, and it was fully approved in July 2012. Starting in November  
9 2012, DOACs were used more frequently than VKAs as initial anticoagulant therapy. The  
10 reimbursement of rivaroxaban was fully approved in September 2012, and the drug was  
11 used more frequently than dabigatran as initial anticoagulant therapy as of January 2013.  
12 This rapid uptake of DOACs in the drug market may be explained by the fact that alternatives  
13 to VKAs had long been expected. Indeed, a recent study indicates that DOACs were  
14 considered equal or preferred to VKAs by respectively 48.5% and 33.3% of surveyed  
15 physicians.<sup>32</sup> The speed of adoption of DOACs is similar to that described for other new  
16 drugs, which usually reaches a plateau 6 to 12 months after they are launched.<sup>33</sup> This speed  
17 varies according to the specialty of the prescriber, and specialists are generally more prompt  
18 to adopt new drugs<sup>33</sup>—as was the case in our study. Nevertheless, some studies have  
19 reported no impact of physician specialty on the prescription of DOACs.<sup>27,30</sup> The differences  
20 we observed between the prescriptions of general practitioners (GP) and those of  
21 cardiologists may reflect the gap between national and European clinical guidelines. Indeed,  
22 French Health Authorities recommend VKAs as initial anticoagulant therapy, whereas the  
23 European Society of Cardiology favors DOACs.<sup>3</sup> GPs in the rest of Europe have taken a more  
24 cautious approach towards DOACs. This is especially the case in the treatment of elderly  
25 populations, most likely because there remains substantial uncertainty concerning the  
26 effectiveness and safety of DOACs in unselected elderly patients with NVAF.<sup>34</sup>



1  
2  
3  
4  
5 Our results indicate that the characteristics of patients who initiated treatment with DOACs  
6 rather than VKAs evolved over the first few years of drug commercialisation. In the first year,  
7 we observed a selection process with healthier patients using DOACs more frequently than  
8 VKAs as initial therapy.<sup>31</sup> This tendency was reinforced as DOAC initiators became healthier  
9 over time. It may reflect the evolution of the perception of efficacy and safety of these new  
10 drugs by physicians. The prescription of DOACs to healthier patients is an issue that needs to  
11 be addressed, as these molecules may offer higher-risk patients greater benefits than  
12 VKAs,<sup>35</sup> but also because their cost effectiveness depends on the severity of patients'  
13 condition.<sup>36</sup> Observational studies that aim to evaluate the risks and benefits associated with  
14 DOACs as well as cost effectiveness studies should carefully account for the fact that  
15 patients selected to initiate DOAC treatment are healthier overall, as well as for the selection  
16 of patients on the different types of DOACs.<sup>37</sup> Failure to do so may lead to underestimating  
17 the potential risks associated with DOACs in real life studies.

18  
19 The fact that DOAC initiation is less frequent among patients with comorbidities may result  
20 from a warning issued by different health agencies such as in France, Europe or US.<sup>35</sup> This  
21 tendency seems to be linked to the diminishing use of dabigatran observed at the end of  
22 2013, when the French medicine safety agency released warnings on bleeding risks  
23 associated with the drug.<sup>38,39,40</sup> At the time, French health authorities informed health  
24 professionals that DOACs are not recommended as initial therapy for NVAf, unless the  
25 patient has poor adherence to VKAs or unless biological monitoring of VKA treatment is  
26 difficult. However, while these recommendations were followed by a temporary decrease in  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 DOAC use, a few months later DOACs were once again the most frequently prescribed  
4  
5 anticoagulants for patients newly treated for NVAF.  
6  
7

8  
9  
10 Our study has several strengths. The source database covers 66 million inhabitants and  
11  
12 nearly 99% of the French population, which means that our findings are independent of  
13  
14 individual health coverage. Moreover, we had access to exhaustive information on  
15  
16 anticoagulant delivery because these treatments are delivered on prescription alone. As a  
17  
18 result, our study is the largest to report penetration of DOACs on the market (particularly in  
19  
20 the case of apixaban, which is the most recent DOAC available) and to describe variations in  
21  
22 the characteristics of patients over time.  
23  
24

25  
26  
27  
28 Nevertheless, some limitations must also be acknowledged. The NHIS administrative  
29  
30 database does not include clinical or biological results; nor does it include outpatients'  
31  
32 diagnosis codes. To capture outpatient diagnosis of AF, we based our definition of NVAF on  
33  
34 drug dispensation, using the most likely treatment scheme for NVAF. Insofar as the results of  
35  
36 our sensitivity analyses are consistent, we can be confident that our findings are not too  
37  
38 sensitive to the definition of NVAF. Moreover, 69% of patients who were hospitalised during  
39  
40 follow-up had a diagnostic code of NVAF in the hospital discharge database (data not  
41  
42 shown). Another limitation of our study is due to the 2015 data that may be partially  
43  
44 incomplete. Indeed, for patients who do not have their NHIS card and attend a pharmacy  
45  
46 that is not their regular pharmacy - a paper reimbursement form may be issued. The data  
47  
48 are then recorded when the paper form is sent to the NHIS and integrated later in the  
49  
50 database. When the 2015 data were made available, paper claims were likely to have not all  
51  
52  
53  
54  
55

1  
2  
3 been included. However, this changes the total number of users but not the proportion of  
4  
5 users of the different drugs.  
6  
7

8  
9  
10 The rapid and massive adoption of DOACs as initial therapy for NVAF will impact treatment  
11  
12 expenditures because of the important increase in costs associated with these new drugs (in  
13  
14 the US, these costs accounted for more than 90% of insurer spending on anticoagulants in  
15  
16 2014<sup>31</sup>). Future observational studies should carefully account for the fact that patients  
17  
18 selected to initiate DOAC treatment are healthier overall, and that this tendency is  
19  
20 reinforced over the first few years of drug commercialization. Failure to do so may bias the  
21  
22 risk-benefit assessment of DOACs.  
23  
24

#### 25 26 27 28 *Contributor ship statement*

29  
30 LH, XR, CF designed the study. All authors have contributed substantially to the  
31  
32 interpretation of results. In addition: LH and AB drafted the article; - CF conducted the  
33  
34 statistical analysis; CF, CR, SL, LB, SS, OM, XR provided critical revision of the manuscript for  
35  
36 important intellectual content. All authors had full access to all of the data (including  
37  
38 statistical reports and tables) in the study and can take responsibility for the integrity of the  
39  
40 data and the accuracy of the data analysis. All authors approved the version to be published.  
41  
42  
43

#### 44 45 46 *Competing interests*

47  
48 Pr. Suissa has participated in advisory board meetings and received research grants from  
49  
50 Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb and Novartis. These activities are  
51  
52 conducted outside this submitted study.  
53  
54

1  
2  
3 All other co-authors have no conflict of interest.  
4  
5

6  
7 *Funding*  
8

9 This research was supported by a 2012 research grant from the Agence Nationale de  
10 Sécurité du Médicament (ANSM).  
11  
12  
13

14  
15  
16 *Data sharing statement*  
17

18 No additional data are available directly from the authors. The datasource of the study is the  
19 French National Health Insurance. Data are available from the Caisse National de l'Assurance  
20 Maladie des Travailleurs Salariés (CNAMTS) for academic research.  
21  
22  
23  
24

25  
26  
27  
28 *Ethics approval*  
29

30 The study was approved by the French National Institute of Data, and by the National  
31 Commission for Data Protection and Liberties (CNIL-France: authorization number:  
32 1637014).  
33  
34  
35  
36  
37  
38

39  
40 *Acknowledgements*  
41

42 We thank the Caisse National de l'Assurance Maladie des Travailleurs Salariés (CNAMTS) and  
43 the Institut des Données de Santé (IDS) for their assistance in obtaining the study database.  
44

45 We personally thank Ms. Valérie EDEL from the IDS, as well as Mr. Laurent DUCHET and Mr.  
46 Medhi GABBAS from the department in charge of the SNIIRAM DATA at CNAM-TS.  
47  
48  
49  
50  
51  
52  
53  
54  
55

We are indebted to Arianne Dorval for proofreading the English manuscript. C Renoux is the recipient of a Chercheur-Boursier Award from the Fonds de la recherche du Québec - santé (FRQ-S). S Suissa is the recipient of the James McGill Chair.

## References

1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 2004; **110**(9): 1042-6.
2. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. *International journal of cardiology* 2013; **167**(5): 1807-24.
3. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* 2012; **14**(10): 1385-413.
4. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology* 2014; **64**(21): e1-76.
5. Jones C, Pollit V, Fitzmaurice D, Cowan C. The management of atrial fibrillation: summary of updated NICE guidance. *BMJ* 2014; **348**: g3655.
6. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *The Canadian journal of cardiology* 2014; **30**(10): 1114-30.
7. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**(2 Suppl): e531S-75S.
8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Annals of internal medicine* 2007; **146**(12): 857-67.
9. De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. *Thrombosis and haemostasis* 2013; **109**(4): 569-79.
10. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. *Annals of internal medicine* 1996; **124**(11): 970-9.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *The New England journal of medicine* 2009; **361**(12): 1139-51.
12. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *The New England journal of medicine* 2011; **365**(10): 883-91.

13. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *The New England journal of medicine* 2011; **365**(11): 981-92.
14. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; **383**(9921): 955-62.
15. Potpara TS, Lip GY. Novel oral anticoagulants in non-valvular atrial fibrillation. *Best Pract Res Clin Haematol* 2013; **26**(2): 115-29.
16. Shields AM, Lip GY. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. *J Intern Med* 2015; **278**(1): 1-18.
17. Haute Autorité de Santé. Fibrillation auriculaire non valvulaire - Quelle place pour les anticoagulants oraux non antivitamine K: apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®). 2013. [http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-07/fs\\_bum\\_naco\\_v5.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-07/fs_bum_naco_v5.pdf).
18. Ferdynus C, Huiart L. [Technical improvement of cohort constitution in administrative health databases: Providing a tool for integration and standardization of data applicable in the French National Health Insurance Database (SNIIRAM)]. *Rev Epidemiol Sante Publique* 2016; **64**(4): 263-9.
19. Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. *Pharmacoepidemiology and drug safety* 2017; **26**(8): 954-62.
20. Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! *Pharmacoepidemiology and drug safety* 2010; **19**(3): 256-65.
21. Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. *Fundamental & clinical pharmacology* 2016; **30**(6): 616-24.
22. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010; **138**(5): 1093-100.
23. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010; **137**(2): 263-72.
24. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. *Circulation Cardiovascular quality and outcomes* 2012; **5**(5): 615-21.
25. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory Oral Anticoagulant Use. *The American journal of medicine* 2015; **128**(12): 1300-5 e2.
26. Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral anticoagulants in UK primary care. *Br J Clin Pharmacol* 2017; **83**(9): 2096-106.
27. Steinberg BA, Holmes DN, Piccini JP, et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. *Journal of the American Heart Association* 2013; **2**(6): e000535.
28. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. *BMJ open* 2013; **3**(5).

- 1
- 2
- 3 29. Lip GY, Laroche C, Dan GA, et al. 'Real-world' antithrombotic treatment in atrial
- 4 fibrillation: The EORP-AF pilot survey. *The American journal of medicine* 2014; **127**(6): 519-29
- 5 e1.
- 6 30. Mochalina N, Joud A, Carlsson M, et al. Antithrombotic therapy in patients with non-
- 7 valvular atrial fibrillation in Southern Sweden: A population-based cohort study. *Thrombosis*
- 8 *research* 2016; **140**: 94-9.
- 9 31. Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral
- 10 anticoagulants in patients with atrial fibrillation- quality and cost implications. *The American*
- 11 *journal of medicine* 2014; **127**(11): 1075-82 e1.
- 12 32. Larsen TB, Potpara T, Dagnes N, Proclemer A, Sciarrafia E, Blomstrom-Lundqvist C.
- 13 Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in
- 14 different clinical situations: results of the European Heart Rhythm Association Survey.
- 15 *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the*
- 16 *working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the*
- 17 *European Society of Cardiology* 2015; **17**(5): 819-24.
- 18 33. Garjon FJ, Azparren A, Vergara I, Azaola B, Loayssa JR. Adoption of new drugs by
- 19 physicians: a survival analysis. *BMC health services research* 2012; **12**: 56.
- 20 34. Opstelten W, van den Donk M, Kuijpers T, Burgers J. New oral anticoagulants for
- 21 nonvalvular atrial fibrillation in the elderly: Limited applicability in primary care. *The*
- 22 *European journal of general practice* 2015; **21**(2): 145-9.
- 23 35. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. *Jama*
- 24 **2015**; **313**(19): 1950-62.
- 25 36. Wisloff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran,
- 26 rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. *PharmacoEconomics*
- 27 **2014**; **32**(6): 601-12.
- 28 37. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative
- 29 effectiveness of newly marketed medications: methodological challenges and implications
- 30 for drug development. *Clinical pharmacology and therapeutics* 2011; **90**(6): 777-90.
- 31 38. Agence Nationale de Sécurité du Médicament et des produits de santé. Nouveaux
- 32 anticoagulants oraux Eliquis (apixaban), Pradaxa (dabigatran), Xarelto (rivaroxaban) : mise en
- 33 garde sur les facteurs de risques hémorragiques - Lettre aux professionnels de santé. 2013.
- 34 39. Haute Autorité de Santé. Les anticoagulants oraux antivitaminé K restent la référence
- 35 dans la fibrillation auriculaire non valvulaire - Communiqué de presse. 2013.
- 36 40. Haute Autorité de Santé. Point sur l'utilisation des nouveaux anticoagulants oraux -
- 37 Communiqué de Presse. 2013 [cited; Available from: [http://www.has-](http://www.has-sante.fr/portail/jcms/c_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux)
- 38 [sante.fr/portail/jcms/c\\_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-](http://www.has-sante.fr/portail/jcms/c_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux)
- 39 [oraux](http://www.has-sante.fr/portail/jcms/c_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux)
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1  
2  
3 **Figure 1 – Flow-chart describing cohort constitution**  
4  
5

6  
7 **Figure 2 – Time trends in the prescription of anticoagulants in newly treated patients with**  
8  
9 **Atrial Fibrillation between 2011 and 2015 in France (n = 814,446)**  
10


11 (VKA: vitamin K antagonist, DOAC: direct oral anticoagulant)  
12

13  
14 Significant changepoints in trends identified a segmented regression model (a): Dabigatran  
15 reimbursement approval, (b): Rivaroxaban reimbursement approval, (c): and Apixaban  
16 reimbursement approval, (d): Security warning (risks of bleeding hemorrhages) from the  
17 National Health Agency, (e): Downgrade of Dabigatran reimbursement.  
18  
19  
20  
21  
22  
23  
24

25 **Figure 3 – HAS-BLED and CHA2DS2-VASc scores associated with DOAC vs VKA initiation**  
26  
27 **according to year of therapy initiation. Crude Odds Ratio and 95% confidence interval**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




180x260mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



164x220mm (300 x 300 DPI)



168x150mm (300 x 300 DPI)

only

**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015)**

*	VKA*	DOACs <sup>†</sup>
	N = 289,430	N = 199,016
<b>Demographic characteristics</b>		
Mean age (sd <sup>§</sup> )	76.1 (11.2)	73.7 (11.3)
Male	49.8%	52.5%
<b>Clinical characteristics<sup>  </sup></b>		
High blood pressure	91.9%	88.7%
Ischemic heart disease	26.3%	16.6%
Heart failure	34.4%	21.6%
Diabetes	21.9%	18.6%
Cancer	16.1%	13.0%
Renal failure	9.7%	2.4%
Liver failure	1.3%	0.7%
Dementia	4.6%	2.7%
History Ischemic stroke	8.5%	6.2%
History of bleeding	5.5%	2.9%
HAS-BLED score, mean (sd)	2.6 (0.9)	2.4 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> score, mean (sd)	3.9 (1.5)	3.4 (1.5)
<b>Other treatment at cohort entry<sup>¶</sup></b>		
Aspirin	45.9%	42.2%
Nonsteroidal anti-inflammatory drugs	13.8%	15.9%
Antiplatelet Agents (other than Aspirin)	14.4%	10.9%
Corticosteroids	13.9%	12.8%
<b>Prescriber of first anticoagulant</b>		
General Practitioner	59.7%	46.7%
<i>Among general practitioners</i>	65.0%	35.0%
Cardiologist	27.7%	43.8%
<i>Among cardiologists</i>	47.9%	52.1%
Other specialist	4.2%	3.8%
Unknown	8.4%	5.6%

Vitamin K agonist; <sup>†</sup> Direct oral anticoagulants; <sup>‡</sup>, p value comparing VKA vs DOACs; <sup>§</sup> sd: standard deviation; <sup>||</sup> defined in the 12 months prior to cohort entry; <sup>¶</sup> defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 2 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation in the Sub-Group of Patients Receiving a Direct Oral Anticoagulant (2011-2015)**

	<b>Dabigatran</b> <b>N = 65,851</b>	<b>Rivaroxaban</b> <b>N = 104,936</b>	<b>Apixaban</b> <b>N = 28,229</b>
<b>Demographic characteristics</b>			
Mean age (sd) <sup>†</sup>	73.7 (11.4)	73.0 (11.3)	76.0 (11.0)
Male	52.3%	53.4%	49.6%
<b>Clinical characteristics<sup>‡</sup></b>			
High blood pressure	88.7%	87.8%	91.8%
Ischemic heart disease	17.9%	15.8%	17.0%
Heart failure	22.8%	19.9%	25.2%
Diabetes	18.6%	18.3%	20.0%
Cancer	14.0%	12.8%	11.3%
Renal failure	2.1%	2.2%	3.8%
Liver failure	0.7%	0.6%	0.6%
Dementia	2.8%	2.6%	2.9%
History of ischemic stroke	7.2%	5.4%	7.1%
History of bleeding	2.7%	2.7%	3.6%
HAS-BLED score, mean (sd)	2.4 (0.9)	2.3 (0.9)	2.5 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> -VASC <sub>2</sub> , mean (sd)	3.4 (1.5)	3.2 (1.5)	3.6 (1.4)
<b>Other treatments at cohort entry<sup>§</sup></b>			
Aspirin	43.0%	41.4%	43.2%
Nonsteroidal anti-inflammatory drugs	16.6%	16.1%	13.2%
Antiplatelet Agents (other than Aspirin)	11.3%	10.4%	12.1%
Corticosteroids	12.8%	12.8%	12.6%
<b>Prescriber of first anticoagulant</b>			
General Practitioner	47.0%	46.3%	47.5%
Cardiologist	43.1%	44.9%	41.7%
Other specialist	3.7%	3.8%	4.1%
Unknown	6.2%	5.0%	6.7%

\* Direct oral anticoagulants, † Standard deviation, ‡ defined in the 12 months prior to cohort entry, § defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 3 – Multivariate analysis of the determinants associated with DOAC initiation according to year of therapy initiation**

Characteristics at treatment initiation	2011 N = 101,817		2012 N = 110,571		2013 N = 103,594		2014 N = 94,180		2015 N = 78,284	
	Adjusted OR	CI 95%*	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%
<b>Demographic characteristics</b>										
Age										
< 65 years	0.89	0.78 – 1.01	0.93	0.88 – 0.97	1.02	0.98 – 1.06	1.15	1.10 – 1.21	1.08	1.03 – 1.14
65 –74 years	1.0		1.0		1.0		1.0		1.0	
>= 75 years	1.15	1.04 – 1.27	0.98	0.94 – 1.01	0.69	0.67 – 0.71	0.59	0.57 – 0.61	0.65	0.63 – 0.68
Sex (Male)	0.86	0.79 – 0.94	0.97	0.94 – 1.01	1.09	1.06 – 1.13	1.10	1.06 – 1.13	1.08	1.05 – 1.12
<b>Clinical characteristics<sup>†</sup></b>										
High blood pressure	0.87	0.76 – 1.00	0.82	0.78 – 0.86	0.79	0.75 – 0.83	0.78	0.74 – 0.82	0.79	0.74 – 0.84
Ischemic heart disease	0.88	0.79 – 0.97	0.83	0.80 – 0.86	0.76	0.74 – 0.79	0.74	0.72 – 0.77	0.76	0.72 – 0.79
Heart failure	0.60	0.55 – 0.67	0.70	0.68 – 0.72	0.61	0.59 – 0.63	0.59	0.57 – 0.61	0.63	0.60 – 0.65
Diabetes	0.88	0.79 – 0.98	0.89	0.86 – 0.93	0.88	0.85 – 0.91	0.93	0.89 – 0.96	0.92	0.89 – 0.96
Cancer	0.98	0.88 – 1.10	0.96	0.92 – 1.00	0.85	0.81 – 0.88	0.85	0.81 – 0.88	0.84	0.80 – 0.89
Renal failure	0.50	0.39 – 0.63	0.34	0.31 – 0.36	0.23	0.22 – 0.25	0.22	0.20 – 0.23	0.24	0.23 – 0.26
Liver failure	0.59	0.33 – 1.05	0.74	0.63 – 0.88	0.59	0.52 – 0.68	0.58	0.50 – 0.66	0.49	0.41 – 0.58
Dementia	0.96	0.77 – 1.19	0.84	0.77 – 0.92	0.75	0.70 – 0.80	0.81	0.76 – 0.88	0.74	0.68 – 0.81
History of Ischemic Stroke	1.01	0.87 – 1.16	0.99	0.94 – 1.05	0.88	0.84 – 0.93	0.88	0.84 – 0.93	0.92	0.86 – 0.98
History of bleeding	1.28	1.06 – 1.55	0.70	0.64 – 0.76	0.52	0.48 – 0.55	0.52	0.49 – 0.56	0.57	0.53 – 0.61
<b>Prescriber of first anticoagulant</b>										
General Practitioner	1.0		1.0		1.0		1.0		1.0	
Cardiologist	1.30	1.19 – 1.42	2.33	2.25 – 2.41	2.63	2.55 – 2.71	2.57	2.49 – 2.65	2.46	2.37 – 0.56
Other specialists/Unknown	1.72	1.52 – 1.93	1.03	0.97 – 1.08	1.00	0.96 – 1.05	1.03	0.98 – 1.07	1.03	0.98 – 1.08
<b>Other treatments at cohort entry<sup>‡</sup></b>										
Aspirin	1.28	1.18 – 1.42	1.16	1.12 – 1.19	0.98	0.85 – 1.00	0.93	0.90 – 0.95	0.87	0.84 – 0.90
NSAID	1.37	1.24 – 1.52	1.16	1.11 – 1.21	1.18	1.13 – 1.22	1.21	1.17 – 1.27	1.20	1.14 – 1.26
Antiplatelet Agents	1.30	1.15 – 1.46	1.06	1.01 – 1.11	0.85	0.82 – 0.89	0.73	0.70 – 0.76	0.78	0.74 – 0.82
Corticosteroids	0.90	0.79 – 1.02	0.96	0.92 – 1.00	0.93	0.89 – 0.96	0.98	0.94 – 1.02	0.92	0.88 – 0.96
<b>Time of anticoagulant initiation</b>										
1 <sup>st</sup> term of the year	1.0		1.0		1.0		1.0		1.0	
2 <sup>nd</sup> term of the year	1.13	0.96 – 1.32	3.17	2.98 – 3.37	1.00	0.96 – 1.04	1.08	1.04 – 1.13	1.11	1.06 – 1.15
3 <sup>rd</sup> term of the year	2.05	1.77 – 2.37	9.37	8.84 – 9.94	0.93	0.89 – 0.96	1.09	1.05 – 1.14	1.17	1.11 – 1.22
4 <sup>th</sup> term of the year	4.71	4.14 – 5.36	31.06	29.34 – 32.88	0.54	0.52 – 0.56	1.35	1.30 – 1.40	1.39	1.33 – 1.45

\* 95% Confidence interval; † defined in the 12 months prior to cohort entry; ‡ defined in the 3 months prior to cohort entry

Supplemental material – Sensitivity analysis – Cohort 2 - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant therapies

Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015).

	VKA*	DOACs <sup>†</sup>
	N = 952,565	N = 661,089
<b>Demographic characteristics</b>		
Mean age (sd <sup>§</sup> )	71.7 (15.3)	69.5 (13.8)
Male	48.4%	49.2%
<b>Clinical characteristics<sup>  </sup></b>		
High blood pressure	78.5%	71.3%
Ischemic heart disease	21.0%	11.9%
Heart failure	18.6%	8.8%
Diabetes	19.9%	15.7%
Cancer	16.7%	11.6%
Renal failure	9.3%	1.9%
Liver failure	1.6%	0.6%
Dementia	5.5%	2.4%
History Ischemic stroke	8.6%	5.0%
History of bleeding	6.8%	3.6%
HAS-BLED score, mean (sd)	2.3 (1.1)	2.0 (1.1)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> score, mean (sd)	3.3 (1.7)	2.8 (1.6)
<b>Other treatment at cohort entry<sup>¶</sup></b>		
Aspirin	35.8%	28.9%
Nonsteroidal anti-inflammatory drugs	17.1%	28.4%
Antiplatelet Agents (other than Aspirin)	11.7%	7.4%
Corticosteroids	15.1%	12.7%
<b>Prescriber of first anticoagulant</b>		
General Practitioner	70.7%	54.1%
<i>Among General Practitioners</i>	64.7%	35.3%
Cardiologist	15.6%	21.7%
<i>Among Cardiologists</i>	50.0%	50.0%
Other specialist	5.8%	18.2%
Unknown	7.9%	6.0%

\* Vitamin K agonist; † Direct oral anticoagulants; ‡, p value comparing VKA vs DOACs; § sd: standard deviation; || defined in the 12 months prior to cohort entry; ¶ defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 2** - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant therapies

**Table 2 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation in the Sub-Group of Patients Receiving a Direct Oral Anticoagulant (2011-2015) AC**

	<b>Dabigatran</b> <b>N = 174,423</b>	<b>Rivaroxaban</b> <b>N = 419,780</b>	<b>Apixaban</b> <b>N = 66,886</b>
<b>Demographic characteristics</b>			
Mean age (sd <sup>†</sup> )	71.5 (12.5)	67.8 (14.3)	74.5 (11.8)
Male	49.6%	49.0%	49.4%
<b>Clinical characteristics<sup>‡</sup></b>			
High blood pressure	76.9%	66.9%	84.4%
Ischemic heart disease	14.8%	10.4%	14.0%
Heart failure	11.0%	6.9%	15.3%
Diabetes	16.9%	14.6%	18.8%
Cancer	12.7%	11.3%	10.8%
Renal failure	1.9%	1.7%	3.7%
Liver failure	0.6%	0.6%	0.6%
Dementia	2.6%	2.2%	3.1%
History of ischemic stroke	6.5%	3.9%	8.4%
History of bleeding	3.5%	3.6%	4.0%
HAS-BLED score, mean (sd)	2.2 (1.0)	1.9 (1.1)	2.4 (1.0)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> , mean (sd)	3.0 (1.6)	2.6 (1.6)	3.4 (1.5)
<b>Other treatments at cohort entry<sup>§</sup></b>			
Aspirin	32.8%	25.9%	37.6%
Nonsteroidal anti-inflammatory drugs	28.3%	29.8%	19.4%
Antiplatelet Agents (other than Aspirin)	8.7%	6.4%	10.1%
Corticosteroids	11.9%	13.1%	11.7%
<b>Prescriber of first anticoagulant</b>			
General Practitioner	48.2%	56.9%	51.4%
Cardiologist	24.1%	19.6%	29.2%
Other specialist	20.9%	18.0%	12.0%
Unknown	6.8%	5.5%	7.4%

\* Direct oral anticoagulants, † Standard deviation, ‡ defined in the 12 months prior to cohort entry, § defined in the 3 months prior to cohort entry



**Supplemental material – Sensitivity analysis – Cohort 2** - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant therapies

**Table 3 – Multivariate analysis of the determinants associated with DOAC initiation according to year of therapy initiation.**

Characteristics at treatment initiation	2011 N = 319*,372		2012 N = 353,242		2013 N = 327,150		2014 N = 311,352		2015 N =275,538	
	Adjusted OR	CI 95%*	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%
<b>Demographic characteristics</b>										
Age										
< 65 years	0.57	0.56 – 0.59	0.63	0.62 – 0.64	0.74	0.72 – 0.76	0.81	0.79 – 0.82	0.81	0.79 – 0.83
65 –74 years	1.0		1.0		1.0		1.0		1.0	
>= 75 years	0.56	0.55 – 0.58	0.76	0.75 – 0.78	0.69	0.68 – 0.70	0.59	0.58 – 0.60	0.66	0.65 – 0.67
Sex (Male)	0.86	0.84 – 0.88	0.98	0.96 – 0.99	1.09	1.07 – 1.11	1.08	1.06 – 1.09	1.06	1.04 – 1.08
<b>Clinical characteristics<sup>†</sup></b>										
High blood pressure	0.76	0.74 – 0.78	0.90	0.88 – 0.92	0.95	0.93 – 0.97	0.89	0.87 – 0.91	0.87	0.85 – 0.89
Ischemic heart disease	0.78	0.76 – 0.81	0.81	0.79 – 0.83	0.76	0.75 – 0.78	0.74	0.72 – 0.76	0.77	0.75 – 0.80
Heart failure	0.15	0.14 – 0.16	0.56	0.54 – 0.57	0.63	0.62 – 0.64	0.58	0.56 – 0.59	0.64	0.63 – 0.66
Diabetes	0.89	0.86 – 0.92	0.90	0.88 – 0.92	0.89	0.87 – 0.91	0.89	0.87 – 0.91	0.91	0.89 – 0.93
Cancer	0.71	0.69 – 0.73	0.81	0.79 – 0.83	0.75	0.73 – 0.76	0.73	0.72 – 0.75	0.70	0.68 – 0.72
Renal failure	0.29	0.27 – 0.32	0.30	0.29 – 0.32	0.23	0.22 – 0.24	0.22	0.21 – 0.23	0.26	0.25 – 0.27
Liver failure	0.50	0.44 – 0.57	0.50	0.46 – 0.55	0.47	0.43 – 0.50	0.43	0.40 – 0.47	0.40	0.37 – 0.44
Dementia	0.29	0.26 – 0.31	0.56	0.54 – 0.59	0.61	0.59 – 0.63	0.60	0.58 – 0.63	0.63	0.60 – 0.66
History of Ischemic Stroke	0.24	0.22 – 0.26	0.66	0.64 – 0.68	0.76	0.74 – 0.78	0.74	0.72 – 0.76	0.81	0.78 – 0.84
History of bleeding	1.00	0.95 – 1.05	0.70	0.68 – 0.73	0.54	0.52 – 0.56	0.53	0.51 – 0.55	0.54	0.52 – 0.56
<b>Prescriber of first anticoagulant</b>										
General Practitioner	1.0		1.0		1.0		1.0		1.0	
Cardiologist	0.26	0.25 – 0.28	1.91	1.87 – 1.95	2.86	2.80 – 2.92	2.78	2.72 – 2.84	2.67	2.60 – 2.73
Other specialists/Unknown	7.01	6.85 – 7.18	3.76	3.69 – 3.84	1.83	1.79 – 1.87	1.79	1.75 – 1.82	1.55	1.51 – 1.58
<b>Other treatments at cohort entry<sup>‡</sup></b>										
Aspirin	0.71	0.69 – 0.73	1.00	0.98 – 1.02	0.98	0.96 – 1.00	0.91	0.90 – 0.93	0.87	0.85 – 0.88
NSAID	2.77	2.71 – 2.83	1.93	1.90 – 1.97	1.57	1.54 – 1.60	1.56	1.53 – 1.59	1.57	1.53 – 1.60
Antiplatelet Agents	0.64	0.61 – 0.68	0.94	0.91 – 0.97	0.83	0.81 – 0.85	0.75	0.72 – 0.77	0.76	0.73 – 0.78
Corticosteroids	0.60	0.58 – 0.62	0.70	0.68 – 0.72	0.79	0.77 – 0.80	0.84	0.82 – 0.86	0.87	0.85 – 0.89
<b>Time of anticoagulant initiation</b>										
1 <sup>st</sup> term of the year	1.0		1.0		1.0		1.0		1.0	
2 <sup>nd</sup> term of the year	1.02	0.99 – 1.05	1.35	1.32 – 1.38	1.05	1.03 – 1.07	1.12	1.10 – 1.14	1.10	1.08 – 1.13
3 <sup>rd</sup> term of the year	0.81	0.78 – 0.83	2.22	2.17 – 2.28	0.96	0.94 – 0.98	1.09	1.07 – 1.12	1.12	1.10 – 1.15
4 <sup>th</sup> term of the year	1.32	1.29 – 1.37	5.92	5.79 – 6.05	0.69	0.68 – 0.70	1.38	1.35 – 1.41	1.31	1.28 – 1.34

\* 95% Confidence interval; † defined in the 12 months prior to cohort entry; ‡ defined in the 3 months prior to cohort entry

Supplementary table – Sources of codes used for the definition of covariates

Covariates at cohort entry	Definitions			
	Drug claims	Hospital discharge diagnoses (main or associated)	Hospital Inpatient procedures	Long duration disease codes
High blood pressure	X	X		X
Ischemic heart disease		X		
Heart failure	X	X		X
Diabetes	X	X		X
Cancer	X	X		X
Renal failure		X	X	X
Liver failure		X		X
Dementia	X	X		X
History Ischemic stroke		X		X
History of bleeding	X	X		
HAS-BLED score	X	X	X	X
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> score	X	X		X
Aspirin	X			
Nonsteroidal anti-inflammatory drugs	X			
Antiplatelet Agents (other than Aspirin)	X			
Corticosteroids	X			

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	Database study – NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	Administrative database study – no missing variable

		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Only variable at cohort entry were used
		(e) Describe any sensitivity analyses	9
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	11 and figure 1
		(c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	NA – admin database study – no missing variables
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Variables only at cohort entry
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	Table 1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary table
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on	14

1  
2  
3  
4 which the present article is based  
5

6 \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

7 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE  
8 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
9 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only

# BMJ Open

## Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French Health Insurance databases

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018180.R2
Article Type:	Research
Date Submitted by the Author:	12-Dec-2017
Complete List of Authors:	Huiart, Laetitia; CIC 1410 Ferdynus, Cyril; CHU de la Réunion, Unité de Soutien Méthodologique; CHU Réunion, CIC INSERM 1410 Renoux, Christel; McGill University, Neurology & Neurosurgery Beaugrand, Amélie; Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Lafarge, Sophie; CHU Réunion, CIC INSERM 1410 Bruneau, Léa; CHU de la Réunion, Unité de Soutien Méthodologique Suissa, Samy; McGill University, Maillard, Olivier; CHU Réunion, CIC INSERM 1410 Ranouil, Xavier; CHU de la Réunion, Service de Cardiologie
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Cardiovascular medicine, Pharmacology and therapeutics, Public health
Keywords:	Cohort, Atrial Fibrillation, anticoagulants, Vitamine K antagonist, direct oral anti-coagulants

SCHOLARONE™  
Manuscripts

1 **Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national**  
2 **population-based cross-sectional study in the French Health Insurance databases**  
3  
4  
5  
6  
7

8 Laetitia Huiart (1,2,3,4), Cyril Ferdynus (1,2), Christel Renoux (5,6,7), Amélie Beaugrand (1,8),  
9  
10 Sophie Lafarge (2), Léa Bruneau (1,4), Samy Suissa (5,7), Olivier Maillard (2,4), Xavier Ranouil  
11  
12 (9)  
13  
14  
15

16  
17  
18 Names of Authors:

19  
20 1 - CHU de la Réunion, Unité de Soutien Méthodologique, Saint-Denis, France  
21

22 2 - CHU de la Réunion, INSERM, CIC 1410, Saint-Pierre, France.  
23

24 3 - Université de La Réunion, UFR Santé, Saint-Denis, France  
25

26  
27 4 - INSERM, Université d'Aix-Marseille, IRD, UMR912 "Sciences Économiques et Sociales de  
28 la Santé et Traitement de l'Information Médicale" (SESSTIM), F-13006 Marseille, France.  
29

30  
31 5 - Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Jewish  
32 General Hospital, Montréal, QC, Canada.  
33

34  
35 6 - Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada.  
36

37  
38 7 - Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, Canada  
39

40  
41 8 - Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France  
42

43 9 - CHU de la Réunion, Service de cardiologie, Saint-Denis, France  
44  
45  
46

47 Corresponding author: telephone number, fax number and e-mail address  
48

- 49 • Name: Laetitia Huiart
- 50
- 51
- 52 • Institution: INSERM
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- Mail: Unité de Soutien Méthodologique, CIC 1410, CHU La Réunion, Allée Topaze,  
97400 Saint-Denis
- Tel and FAX numbers : +262.2.62.90.68.82 / fax: +262.2.62.90.69.21
- e- mail: laetitia.huiart@mail.mcgill.ca

For peer review only



**Abstract (300 words)***Objective*

Unlike several other national health agencies, French health authorities recommended that the newer direct oral anticoagulant (DOAC) agents only be prescribed as second choice for the treatment of newly diagnosed non-valvular atrial fibrillation (NVAf), with vitamin K antagonists (VKA) remaining the first choice. We investigated the patterns of use of DOACs versus VKA in the treatment of NVAf in France over the first five years of DOAC availability. We also identified the changes in patient characteristics of those who initiated DOAC treatment over this time period.

*Methods*

Based on the French National Health Administrative Database, we constituted a population-based cohort of all patients who were newly treated for NVAf between January 2011 and December 2015. Trends in drug use were described as the percentage of patients initiating each drug at the time of treatment initiation. A multivariate analysis using logistic regression model was performed to identify independent sociodemographic and clinical predictors of initial anticoagulant choice.

*Results*

The cohort comprised 814,446 patients who had received a new anticoagulant treatment for NVAf. The proportion of patients using DOACs as initial anticoagulant therapy reached 54% three months after the Health Ministry approved the reimbursement of dabigatran for NVAf, and 61% by the end of 2015, versus VKA use. In the multivariate analysis, we found that DOAC initiators were younger and healthier overall than VKA initiators, and this tendency was reinforced over the 2011-2014 period. DOACs were more frequently

1 prescribed by cardiologists in 2012 and after (adjusted-OR in 2012: 2.47; 95% Confidence  
2 Interval: 2.40-2.54).  
3  
4

### 5 *Conclusion*

6  
7  
8 Despite recommendations from health authorities, DOACs have been rapidly and massively  
9 adopted as initial therapy for NVAF in France. Observational studies should account for the  
10 fact that patients selected to initiate DOAC treatment are healthier overall, as failure to do  
11 so may bias the risk-benefit assessment of DOACs.  
12  
13  
14  
15

16  
17  
18 **Keywords (6 max)**

19 Cohort, atrial fibrillation, anticoagulants, vitamin K antagonist, direct oral anticoagulants  
20  
21

22 **Tables: 2**

23  
24 **Figures: 3**

25  
26  
27 **Supplementary material: 6 tables**  
28  
29  
30  
31  
32  
33

### 34 **Strength and limitations:**

- 35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- With a source database covering 66 million inhabitants and exhaustive information on anticoagulant deliveries in France, our study is the largest to report penetration of DOACs on the market. This is particularly the case for apixaban, which was the most recent DOAC available at the time of the study
  - The administrative database used does not include clinical results; nor does it include outpatients' diagnosis codes. To account for outpatients, we based our definition of NVAF on drug dispensation, using the most likely treatment scheme for NVAF. We conducted sensitivity analyses to ensure that our results are consistent.

## Introduction

Non-Valvular Atrial fibrillation (NVAf) is the most common sustained cardiac arrhythmia, and its age-adjusted prevalence has been increasing over time.<sup>1,2</sup> NVAf is associated with high morbidity and mortality, as it increases the risks of stroke and systemic thromboembolic events.<sup>2</sup> In light of this, the use of an oral anticoagulant is recommended in patients with NVAf at medium or high risk of stroke.<sup>3-7</sup> For more than 50 years, vitamin K antagonists (VKA) such as warfarin were the only effective therapy available for stroke prevention in patients with NVAf.<sup>8</sup> However, the efficacy and safety of VKAs are closely related to the quality of anticoagulation, which is open to substantial inter- and intra-patient variability and requires close biological monitoring.<sup>9, 8,10</sup>

In order to respond to physicians' and patients' expectations of more user-friendly drugs, research on new drugs has intensified over the last few years. This has prompted the development of direct oral anticoagulants (DOAC) that inhibit thrombin or factor Xa. Large randomised clinical trials (RCTs) have compared the efficacy of DOACs to that of warfarin in patients with NVAf.<sup>11, 12,13</sup> A recent meta-analysis of these RCTs has shown that the frequency of strokes and/or systemic embolic events is 19% lower with DOACs than it is with warfarin. Moreover, compared with warfarin, DOACs have been shown to present similar risks of major bleeding but higher risks of gastrointestinal bleeding.<sup>14</sup> The benefit-risk ratio of DOACs nevertheless varies across individual agents, and also according to patient profile.<sup>15,16</sup>

In France, the direct thrombin inhibitor dabigatran was the first DOAC to be approved for the primary prevention of venous thromboembolism in orthopedic surgery (in 2008) and stroke in NVAf (in 2011). Reimbursement of dabigatran for the treatment of NVAf was approved in July 2012. Two new oral direct factor Xa inhibitors, rivaroxaban and apixaban, were made available for patients with NVAf in September 2012 and January 2014,

1 respectively. Given the initial lack of specific antidotes and of data on these drugs' efficacy  
2 and safety in real life, French Health Authorities recommended that VKAs remain the  
3  
4 and safety in real life, French Health Authorities recommended that VKAs remain the  
5  
6 standard therapy. They also recommended that DOACs be offered as an alternative therapy  
7  
8 only to patients with low adherence to VKAs or unstable INRs (International Normalised  
9  
10 Ratios) on VKAs.<sup>17</sup> To date, it is not clear how the expectations of clinicians and the  
11  
12 recommendations of health authorities have impacted the choice of anticoagulant for newly  
13  
14 treated patients with NVAf. Nor is it clear how patients' characteristics have influenced  
15  
16 treatment choice.  
17

18  
19  
20 In view of the above, we conducted a study in the French National health administrative  
21  
22 database. This study based on claims data, aimed to identify the initial oral anticoagulant  
23  
24 therapy used in a cohort of patients newly diagnosed with NVAf for the prevention of stroke  
25  
26 and systemic thromboembolism. It also sought to describe changes in the characteristics of  
27  
28 patients who initiated treatment during the first five years of DOAC availability in France.  
29  
30

## 31 32 33 **Method**

### 34 35 *Study design and source of data*

36  
37  
38 The retrospective population-based cohort of patients with NVAf was formed from data  
39  
40 provided by the French National Health Insurance System (NHIS).<sup>18</sup> The NHIS guarantees  
41  
42 universal health coverage to all segments of the population, and includes both a drug  
43  
44 delivery database and a hospital discharge database. The NHIS comprises health insurance  
45  
46 schemes for salaried workers, self-employed workers, agricultural workers and farmers, as  
47  
48 well as 12 other insurance schemes. Together, these schemes provide health insurance to  
49  
50 approximately 66 million inhabitants, which corresponds to approximately 99% of the  
51  
52 French population.<sup>19</sup> Detailed description of the NHIS database is provided elsewhere.<sup>20,21</sup>  
53  
54

1 In France, drugs are available only in pharmacies, and a medical prescription is required to  
2 obtain anticoagulant drugs. All reimbursement claims for prescriptions processed and filled  
3 in pharmacies are submitted to the NHIS via a single electronic system. This drug delivery  
4 database is linked to the hospital discharge database through a unique personal identifier  
5 allocated to every individual. The second database provides medical information on all  
6 patients discharged from hospitals, along with associated ICD-10 diagnosis codes (10<sup>th</sup>  
7 version of International Classification of Diseases). However, no clinical diagnosis is provided  
8 in this database for consultations by health professionals in an ambulatory care setting.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

### 22 *Cohort definition*

23 We defined a cohort of all patients 18 years and older who were newly treated for NVAF  
24 between January 1, 2011 and December 31, 2015. Cohort entry was defined by the delivery  
25 of anticoagulant therapy (VKA or DOAC) combined with either an antiarrhythmic agent  
26 (flecainide, propafenone, amiodarone, quinidine, disopyramide or sotalol) or a rate control  
27 treatment (beta-blocker, calcium channel blockers - verapamil and diltiazem -, or digoxin)  
28 within a time window of +/- 30 days. The date of cohort entry was the latest date of delivery  
29 of either drug, within the 30 day window. We excluded patients with less than 1 year of data  
30 available in the database before cohort entry, as well as patients who had received  
31 anticoagulant treatment or had a history of cardiac valvular replacement in the 12 months  
32 before inclusion. Therefore, the anticoagulant therapy received at cohort inclusion  
33 corresponded to a new anticoagulant therapy. Lastly, we excluded patients who had  
34 undergone lower limb orthopedic surgery within +/- 30 days of inclusion.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

### 52 *Exposure*

1 We identified patients' exposure to initial anticoagulant treatment. We compared patients  
2  
3  
4 initiating VKA treatment—acenocoumarol, fluindione, warfarin (the 3 most commonly used  
5  
6 VKAs in France)—to patients receiving any of the 3 DOACs available during the study period  
7  
8 (dabigatran, rivaroxaban or apixaban).  
9

#### 10 Study covariates

11  
12 The following characteristics of patients were identified in the year prior to cohort entry  
13  
14 using treatment and/or hospital discharge code (supplementary table): high blood pressure,  
15  
16 coronary artery disease (including myocardial infarction and ischemic heart disease),  
17  
18 congestive heart failure, diabetes, a personal history of cancer, renal failure, liver failure,  
19  
20 dementia, a history of bleeding, and history of ischemic stroke. Exposure to treatment other  
21  
22 than anticoagulants—aspirin or other nonsteroidal anti-inflammatory drugs, antiplatelet  
23  
24 agents (other than aspirin), corticosteroids—was identified in the 3 months prior to cohort  
25  
26 entry. We also determined whether initial anticoagulant therapy was prescribed by a general  
27  
28 practitioner, a cardiologist or a physician with another specialty. To estimate the risk of  
29  
30 major bleeding, we calculated a modified HAS-BLED score (hypertension, abnormal renal  
31  
32 and/or liver function, stroke/TIA, bleeding, labile international normalised ratio (INR), age  
33  
34 >65, antiplatelet/NSAID use, or alcohol abuse).<sup>22</sup> Labile INR was not included in the score  
35  
36 because it is unavailable in the database. Alcohol abuse was determined based on the  
37  
38 hospital discharge database. To estimate the risk of stroke, we calculated the CHA2DS2-  
39  
40 VASc2 score (congestive heart failure, hypertension, age  $\geq 75$ , diabetes mellitus,  
41  
42 stroke/transient ischemic attack, vascular disease, age 65–74, and sex).<sup>23</sup>  
43  
44  
45  
46  
47  
48  
49

#### 50 *Data analysis*

51  
52 Descriptive statistics were computed for continuous data (mean, +/- standard deviation (SD)  
53  
54 or median and range) and for categorical data (frequency and proportion). Trends in drugs  
55  
56

1 use were described as the number of new patients treated each month and as the  
2  
3  
4 percentage of each anticoagulant prescribed at the time of treatment initiation.  
5

6 Patients' characteristics were described according to initial anticoagulant therapy received.

7  
8 In bivariate comparisons, the characteristics of patients and prescribers were compared  
9  
10 according to the type of anticoagulant, using a t-test for continuous variables, and a chi-  
11  
12 square test for categorical variables. To identify independent predictors of initial  
13  
14 anticoagulant choice, we performed a multivariate analysis using 5 logistic regression  
15  
16 models, one for each calendar year of anticoagulant initiation. The model included all the  
17  
18 variables that were associated with a p-value <0.20 in the bivariate comparisons. These  
19  
20 variables were selected using a backward selection approach. Further, we defined 2 other  
21  
22 cohorts for the sensitivity analyses: 1) one cohort was defined more restrictively: it included  
23  
24 patients who were newly treated with an anticoagulant combined with an antiarrhythmic  
25  
26 agent or a rate control treatment other than beta-blocker agents within a time window of  
27  
28 +/- 30 days; 2) the other cohort was defined according to broader inclusion criteria: it  
29  
30 comprised all patients newly treated with an anticoagulant, regardless of other potential  
31  
32 concomitant therapies.  
33  
34  
35  
36  
37

38 To assess the impact of timeline events on the uptake process (i.e. market authorization of  
39  
40 each drug, reimbursement approval/downgrade and security warnings from national health  
41  
42 agency), we fitted a segmented regression model, adjusted on: 1) drug coded into four  
43  
44 categories (VKA, dabigatran, rivaroxaban and apixaban), 2) time (linear and square terms)  
45  
46 and 3) each timeline event. A timeline event was coded as a dichotomous variable valued 0  
47  
48 before the event and 1 after. All these covariates were included in a primary model, then a  
49  
50 backward selection procedure was applied to select covariates associated at a significant  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 level ( $p < 0.05$ ). To evaluate the trends and the impact of timeline events on each drug, we  
2 entered an interaction term for each drug and other covariates (time and timeline events).  
3

4 Statistical significance was set at 0.05. All p-values were two sided.  
5

6 All statistical analyses were performed using SAS version 9.4 (SAS institute, Cary Inc).  
7  
8  
9

## 10 11 12 13 **Results**

14  
15 In France, 1,772,399 individuals were delivered a prescription for either a VKA or a DOAC  
16 between January 1, 2011 and December 31, 2015 (Figure 1). Out of this sample, we  
17 identified 872,970 individuals who received a new prescription for an anticoagulant (VKA or  
18 DOAC) combined with a prescription for an antiarrhythmic agent or a rate control treatment  
19 within a time window of +/- 30 days. Ultimately, the cohort comprised 814,446 patients  
20 newly treated for NVAf: 506,821 subjects initiated VKA, 94,468 dabigatran, 169,524  
21 rivaroxaban, and 43,633 apixaban.  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 Figure 2 illustrates the percentages of patients initiating one of the different anticoagulant  
32 treatments over the study period. A sharp rise in DOAC use was observed starting in mid-  
33 2012. As of October 2012, DOACs were used more frequently than VKAs as initial  
34 anticoagulant therapy, representing 54% of all anticoagulant prescriptions (30% for  
35 dabigatran and 24% for rivaroxaban). In the last quarter of 2015, this percentage reached  
36 61% (4% for dabigatran, 34% for rivaroxaban, and 24% for apixaban). The proportion of  
37 patients initiating dabigatran began to decline 6 months after reimbursement was approved,  
38 and even more so after October 2013. Rivaroxaban use increased sharply as early as  
39 September 2012. This drug was the most frequently initiated DOAC in early 2013, and it  
40 remained so until December 2015, when it was surpassed by apixaban (26% vs 28% in  
41 December 2015).  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55



1 Figure 2 illustrates the percentages of patients initiating one of the different anticoagulant  
2 treatments over the study period. The segmented regression model identified 5 significant  
3  
4 treatments over the study period. The segmented regression model identified 5 significant  
5  
6 changepoints. The two first changepoints (line a and b in figure 2) corresponded to a sharp  
7  
8 rise in DOAC initiation in July 2012 and in September 2012, corresponding respectively to  
9  
10 dabigatran and rivaroxaban reimbursement approval time. As of October 2012, DOACs were  
11  
12 used more frequently than VKAs as initial anticoagulant therapy, representing 54% of all  
13  
14 anticoagulant prescriptions (30% for dabigatran and 24% for rivaroxaban). The third  
15  
16 changepoint identified was in September 2013 (ligne d, Figure 2) with a significant decrease  
17  
18 in the use of DOACs at the time security warnings were issued by the French health  
19  
20 authorities. From January 2014 (4<sup>th</sup> change point – line c on figure 2), DOACs initiation  
21  
22 increased again, corresponding to the time point where apixaban received reimbursement  
23  
24 approval. A final significant changepoint (line e) was identified in September 2015 and was  
25  
26 linked to a reduction in dabigatran reimbursement. In December 2015, apixaban was the  
27  
28 most prescribed DOAC (28% versus 26% for rivaroxaban).  
29  
30  
31  
32  
33  
34  
35

36 The mean age of newly treated patients was 74.9 (SD: 11.7), and 50.2% of patients were  
37  
38 male (table 1). Most subjects were treated for high blood pressure (94.4%), and 22.2% were  
39  
40 treated for diabetes. Patients who received DOACs had less comorbidities and were on  
41  
42 average younger than those who were prescribed VKAs (73.8 years (SD: 11.5) versus 75.6  
43  
44 years (SD: 11.9)  $p < 0.0001$ ). General practitioners prescribed VKAs (67.5%) more frequently  
45  
46 than DOACs (32.5%) as initial anticoagulant therapy, whereas cardiologist favored DOACs  
47  
48 (51.2%). Patients receiving apixaban were older than those receiving other DOACs (76.2 vs.  
49  
50 72.9 for rivaroxaban and 74.1 for dabigatran). They also had more comorbidities, such as  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 high blood pressure and heart or renal failure (table 1). Patients with lower HAS-BLED or  
2 lower CHA2DS2-VASc scores were more likely to initiate DOACs (figure 3).  
3

4  
5  
6 The characteristics and associated treatments of DOAC initiators as compared with VKA  
7 initiators changed over the 5-year period (table 2). Older subjects ( $\geq 75$  years) were less  
8 likely to initiate DOAC treatment than VKA treatment. The adjusted OR decreased from 0.86  
9 in 2011 (95% Confidence Interval (95%CI): 0.80 to 0.92) to 0.62 in 2014 (95%CI: 0.61 to 0.64).  
10  
11  
12

13  
14  
15 Overall, patients with comorbidities—especially renal failure—were less likely to receive  
16 DOAC treatment, and this negative association was reinforced over the study period  
17 (adjusted OR for 2014: 0.22; 95%CI: 0.21-0.23). The negative association was not reinforced  
18 in 2015, likely due the fact that a larger proportion of patients received apixaban. However,  
19 because apixaban was only available at the end of the study period, further data are needed  
20 to confirm this hypothesis. Patients with a history of bleeding prior to cohort entry were less  
21 likely to receive DOAC treatment (adjusted OR for 2015: 0.56; 95%CI: 0.53-0.59). Since 2012,  
22 cardiologists have been strongly associated with initial prescription of DOACs, after  
23 accounting the patients' characteristics.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 The sensitivity analyses conducted for the 2 other cohorts provided similar results: a rapid  
37 increase in the use of DOAC over time, and a healthier profile of patients receiving DOACs  
38 compared with those receiving VKAs (supplementary material cohort 1 and cohort 2).  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015)**

	VKA* N = 506,821	Dabigatran N = 94,468	Rivaroxaban N = 169,524	Apixaban N = 43,633
<b>Demographic characteristics</b>				
Mean age (sd) <sup>†</sup>	75.6 (11.9)	74.1 (11.3)	73.0 (11.5)	76.2 (11.1)
Male	49.3%	52.3%	52.0%	49.5%
<b>Clinical characteristics<sup>‡</sup></b>				
High blood pressure	95.4%	92.1%	92.5%	94.7%
Ischemic heart disease	28.6%	19.7%	17.4%	17.6%
Heart failure	27.8%	18.9%	15.2%	21.5%
Diabetes	23.6%	19.9%	19.7%	20.8%
Cancer	16.5%	14.0%	12.8%	11.1%
Renal failure	10.9%	2.3%	2.4%	4.1%
Liver failure	1.7%	0.7%	0.7%	0.6%
Dementia	5.2%	3.1%	2.9%	3.3%
History of ischemic stroke	9.6%	8.4%	6.0%	9.0%
History of bleeding	6.3%	2.9%	3.1%	3.9%
HAS-BLED score, mean (sd)	2.7 (0.9)	2.4 (0.9)	2.4 (0.9)	2.5 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> , mean (sd)	3.9 (1.5)	3.5 (1.5)	3.3 (1.4)	3.7 (1.4)
<b>Other treatments at cohort entry<sup>§</sup></b>				
Aspirin	45.8%	43.3%	40.9%	43.6%
Nonsteroidal anti-inflammatory drugs	13.7%	16.6%	16.9%	13.0%
Antiplatelet Agents (other than Aspirin)	15.8%	12.1%	10.9%	12.4%
Corticosteroids	14.0%	12.2%	12.7%	12.1%
Protons-Pump Inhibitors	48.9%	40.7%	41.2%	43.9%
<b>Prescriber of first anticoagulant</b>				
General Practitioner	64.4%	50.2%	51.9%	50.4%
Cardiologist	22.2%	38.9%	38.0%	37.9%
Other specialist	4.8%	4.4%	4.7%	4.6%
Unknown	8.6%	6.5%	5.4%	7.1%

\* Vitamin K agonist; † Direct oral anticoagulants; ‡ sd: standard deviation; § defined in the 12 months prior to cohort entry; || defined in the 3 months prior to cohort entry

**Table 2 – Multivariate analysis of the determinants associated with DOAC initiation according to year of therapy initiation.**

Characteristics at treatment initiation	2011 N = 159,903		2012 N = 177,131		2013 N = 170,431		2014 N = 162,674		2015 N = 144,307	
	Adjusted OR	CI 95%*	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%
Demographic characteristics										
Age										
< 65 years	0.88	0.81 – 0.96	0.82	0.79 – 0.86	0.87	0.84 – 0.90	0.99	0.95 – 1.02	0.94	0.91 – 0.98
65 –74 years	1.0		1.0		1.0		1.0		1.0	
>= 75 years	0.86	0.80 – 0.92	0.98	0.95 – 1.01	0.74	0.72 – 0.76	0.62	0.61 – 0.64	0.68	0.66 – 0.70
Sex (Male)	0.73	0.69 – 0.77	1.01	0.99 – 1.04	1.15	1.12 – 1.17	1.13	1.11 – 1.16	1.11	1.08 – 1.13
Clinical characteristics <sup>†</sup>										
High blood pressure	1.29	1.13 – 1.46	0.74	0.71 – 0.78	0.61	0.58 – 0.64	0.63	0.60 – 0.66	0.62	0.59 – 0.66
Ischemic heart disease	0.89	0.84 – 0.96	0.80	0.78 – 0.83	0.74	0.72 – 0.76	0.70	0.69 – 0.72	0.75	0.73 – 0.77
Heart failure	0.43	0.40 – 0.47	0.73	0.71 – 0.76	0.68	0.66 – 0.69	0.64	0.62 – 0.65	0.69	0.66 – 0.70
Diabetes	0.89	0.83 – 0.96	0.91	0.88 – 0.94	0.89	0.86 – 0.91	0.90	0.88 – 0.92	0.91	0.89 – 0.94
Cancer	0.93	0.86 – 1.01	0.92	0.89 – 0.95	0.82	0.80 – 0.85	0.81	0.79 – 0.83	0.80	0.77 – 0.83
Renal failure	0.45	0.38 – 0.53	0.32	0.30 – 0.35	0.23	0.22 – 0.25	0.22	0.21 – 0.23	0.25	0.24 – 0.27
Liver failure	0.58	0.41 – 0.80	0.58	0.51 – 0.66	0.48	0.44 – 0.53	0.41	0.38 – 0.46	0.40	0.35 – 0.44
Dementia	0.72	0.61 – 0.85	0.79	0.74 – 0.84	0.73	0.69 – 0.77	0.74	0.70 – 0.78	0.72	0.68 – 0.76
History of Ischemic Stroke	0.70	0.63 – 0.78	0.95	0.91 – 1.00	0.91	0.88 – 0.95	0.88	0.85 – 0.91	0.92	0.89 – 0.96
History of bleeding	1.35	1.19 – 1.52	0.68	0.64 – 0.72	0.55	0.52 – 0.58	0.53	0.50 – 0.56	0.56	0.53 – 0.59
Prescriber of first anticoagulant										
General Practitioner	1.0		1.0		1.0		1.0		1.0	
Cardiologist	0.86	0.81 – 0.93	2.47	2.40 – 2.54	2.86	2.79 – 2.93	2.73	2.67 – 2.80	2.57	2.49 – 2.64
Other specialists/Unknown	2.53	2.36 – 2.71	1.15	1.10 – 1.19	1.00	0.96 – 1.03	1.04	1.00 – 1.07	1.03	0.99 – 1.06
Other treatments at cohort entry <sup>‡</sup>										
Aspirin	1.04	0.98 – 1.10	1.13	1.10 – 1.16	0.99	0.97 – 1.01	0.93	0.91 – 0.95	0.87	0.85 – 0.89
NSAID	1.90	1.78 – 2.02	1.17	1.13 – 1.21	1.19	1.16 – 1.22	1.21	1.18 – 1.25	1.24	1.20 – 1.28
Antiplatelet Agents	1.03	0.94 – 1.12	1.03	0.99 – 1.07	0.81	0.79 – 0.84	0.72	0.70 – 0.75	0.74	0.71 – 0.77
Corticosteroids	0.76	0.69 – 0.83	0.87	0.84 – 0.94	0.89	0.86 – 0.91	0.93	0.90 – 0.96	0.93	0.90 – 0.96
Time of anticoagulant initiation										
1 <sup>st</sup> term of the year	1.0		1.0		1.0		1.0		1.0	
2 <sup>nd</sup> term of the year	1.12	1.02 – 1.23	2.85	2.72 – 2.99	1.01	0.98 – 1.04	1.10	1.07 – 1.14	1.13	1.09 – 1.16
3 <sup>rd</sup> term of the year	1.40	1.28 – 1.53	7.53	7.19 – 7.88	0.94	0.91 – 0.97	1.13	1.09 – 1.16	1.19	1.15 – 1.23
4 <sup>th</sup> term of the year	2.75	2.53 – 2.94	22.52	21.55 – 23.54	0.58	0.56 – 0.59	1.38	1.34 – 1.42	1.40	1.36 – 1.44

\* 95% Confidence interval; † defined in the 12 months prior to cohort entry; ‡ defined in the 3 months prior to cohort entry

## Discussion

Less than 6 months after reimbursement was approved, DOACs became the most frequently prescribed initial anticoagulant therapy for NVAF in France. Starting in the third quarter of 2012, DOACs were delivered to over 60% of all patients newly treated for NVAF. Dabigatran, rivaroxaban and, in late 2015, apixaban were used one after the other as the most frequent initial DOAC therapy for NVAF. The proportion of dabigatran initiators declined largely after 2013. DOAC initiators were younger and healthier than VKA users, and this tendency was reinforced over time. The use of DOACs varied over time depending on the availability of new drugs and on the national recommendations and safety warnings in place.

National trends in anticoagulant sales volumes have also been reported in other countries, revealing an important upsurge in DOAC use.<sup>24-26</sup> Most studies based on registries or cohorts of patients with NVAF have reported dabigatran use rates ranging from 5% to 25%, which is lower than what we found in our study.<sup>27-30</sup> However, in the US, Desai *et al.* have reported an increase in DOAC use for the 2010-2013 period which is similar to the one we observed, with a peak of 62% of patients initiating DOAC treatment among a cohort of anticoagulant initiators.<sup>31</sup> These common trends in results observed are surprising given the differences in populations, health systems, drug coverage, and, most importantly, clinical recommendations on the use of DOACs for the treatment of NVAF between countries. Indeed, in France, health authorities do not recommend DOACs as initial anticoagulant therapy, unless the patient has poor adherence to VKAs or unless biological monitoring of VKA treatment is difficult.<sup>17</sup> However, physicians are still free to opt for any of the available treatment and their personal beliefs on efficacy and safety influences their choices.

1  
2  
3  
4  
5 The sharp rise in DOAC use in France was observed as of mid-2012, shortly after the NHIS  
6 approved the reimbursement of dabigatran. Specifically, dabigatran was authorised as an  
7 anticoagulant for the treatment of NVAF in August 2011; reimbursement of treatment was  
8 pre-approved in February 2012, and it was fully approved in July 2012. Starting in November  
9 2012, DOACs were used more frequently than VKAs as initial anticoagulant therapy. The  
10 reimbursement of rivaroxaban was fully approved in September 2012, and the drug was  
11 used more frequently than dabigatran as initial anticoagulant therapy as of January 2013.  
12 This rapid uptake of DOACs in the drug market may be explained by the fact that alternatives  
13 to VKAs had long been expected. Indeed, a recent study indicates that DOACs were  
14 considered equal or preferred to VKAs by respectively 48.5% and 33.3% of surveyed  
15 physicians.<sup>32</sup> The speed of adoption of DOACs is similar to that described for other new  
16 drugs, which usually reaches a plateau 6 to 12 months after they are launched.<sup>33</sup> This speed  
17 varies according to the specialty of the prescriber, and specialists are generally more prompt  
18 to adopt new drugs<sup>33</sup>—as was the case in our study. Nevertheless, some studies have  
19 reported no impact of physician specialty on the prescription of DOACs.<sup>27,30</sup> The differences  
20 we observed between the prescriptions of general practitioners (GP) and those of  
21 cardiologists may reflect the gap between national and European clinical guidelines. Indeed,  
22 French Health Authorities recommend VKAs as initial anticoagulant therapy, whereas the  
23 European Society of Cardiology favors DOACs.<sup>3</sup> GPs in the rest of Europe have taken a more  
24 cautious approach towards DOACs. This is especially the case in the treatment of elderly  
25 populations, most likely because there remains substantial uncertainty concerning the  
26 effectiveness and safety of DOACs in unselected elderly patients with NVAF.<sup>34</sup>

1  
2  
3  
4  
5 Our results indicate that the characteristics of patients who initiated treatment with DOACs  
6 rather than VKAs evolved over the first few years of drug commercialisation. In the first year,  
7 we observed a selection process with healthier patients using DOACs more frequently than  
8 VKAs as initial therapy.<sup>31</sup> This tendency was reinforced as DOAC initiators became healthier  
9 over time. It may reflect the evolution of the perception of efficacy and safety of these new  
10 drugs by physicians. The prescription of DOACs to healthier patients is an issue that needs to  
11 be addressed, as these molecules may offer higher-risk patients greater benefits than  
12 VKAs,<sup>35</sup> but also because their cost effectiveness depends on the severity of patients'  
13 condition.<sup>36</sup> Observational studies that aim to evaluate the risks and benefits associated with  
14 DOACs as well as cost effectiveness studies should carefully account for the fact that  
15 patients selected to initiate DOAC treatment are healthier overall, as well as for the selection  
16 of patients on the different types of DOACs.<sup>37</sup> Failure to do so may lead to underestimating  
17 the potential risks associated with DOACs in real life studies.

18  
19 The fact that DOAC initiation is less frequent among patients with comorbidities may result  
20 from a warning issued by different health agencies such as in France, Europe or US.<sup>35</sup> This  
21 tendency seems to be linked to the diminishing use of dabigatran observed at the end of  
22 2013, when the French medicine safety agency released warnings on bleeding risks  
23 associated with the drug.<sup>38,39,40</sup> At the time, French health authorities informed health  
24 professionals that DOACs are not recommended as initial therapy for NVAf, unless the  
25 patient has poor adherence to VKAs or unless biological monitoring of VKA treatment is  
26 difficult. However, while these recommendations were followed by a temporary decrease in  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 DOAC use, a few months later DOACs were once again the most frequently prescribed  
4  
5 anticoagulants for patients newly treated for NVAF.  
6  
7

8  
9  
10 Our study has several strengths. The source database covers 66 million inhabitants and  
11  
12 nearly 99% of the French population, which means that our findings are independent of  
13  
14 individual health coverage. Moreover, we had access to exhaustive information on  
15  
16 anticoagulant delivery because these treatments are delivered on prescription alone. As a  
17  
18 result, our study is the largest to report penetration of DOACs on the market (particularly in  
19  
20 the case of apixaban, which is the most recent DOAC available) and to describe variations in  
21  
22 the characteristics of patients over time.  
23  
24

25  
26  
27  
28 Nevertheless, some limitations must also be acknowledged. The NHIS administrative  
29  
30 database does not include clinical or biological results; nor does it include outpatients'  
31  
32 diagnosis codes. To capture outpatient diagnosis of AF, we based our definition of NVAF on  
33  
34 drug dispensation, using the most likely treatment scheme for NVAF. Insofar as the results of  
35  
36 our sensitivity analyses are consistent, we can be confident that our findings regarding the  
37  
38 choice of the initial therapy and the patients' characteristics are not too sensitive to the definition  
39  
40 of NVAF. Moreover, 69% of patients who were hospitalised during follow-up had a  
41  
42 diagnostic code of NVAF in the hospital discharge database (data not shown). We did not use  
43  
44 long duration diseases codes to define AF as these codes have various limitation, for  
45  
46 example their use has been shown to differ between the different insurance schemes  
47  
48 included in the database <sup>41</sup> and there was an important discrepancy between them and  
49  
50 hospital discharge codes. These long duration disease codes were only used to define some  
51  
52  
53  
54  
55



1  
2  
3 covariates but only in combination with drugs delivery and/or hospital codes. We did not  
4  
5 exclude patients with Deep Vein Thrombosis or Pulmonary Embolism at inclusion. They  
6  
7 represented 4.4 % of the study sample. We conducted a sensitivity analysis excluding these  
8  
9 patients and obtained similar results (data not shown). Another limitation of our study is due  
10  
11 to the 2015 data that may be partially incomplete. Indeed, for patients who do not have  
12  
13 their NHIS card and attend a pharmacy that is not their regular pharmacy - a paper  
14  
15 reimbursement form may be issued. The data are then recorded when the paper form is  
16  
17 send to the NHIS and integrated later in the database. When the 2015 data were made  
18  
19 available, paper claims were likely to have not all been included. However, this changes the  
20  
21 total number of users but not the proportion of users of the different drugs.  
22  
23  
24  
25  
26  
27

28 The rapid and massive adoption of DOACs as initial therapy for NVAF will impact treatment  
29  
30 expenditures because of the important increase in costs associated with these new drugs (in  
31  
32 the US, these costs accounted for more than 90% of insurer spending on anticoagulants in  
33  
34 2014<sup>31</sup>). Future observational studies should carefully account for the fact that patients  
35  
36 selected to initiate DOAC treatment are healthier overall, and that this tendency is  
37  
38 reinforced over the first few years of drug commercialization. Failure to do so may bias the  
39  
40 risk-benefit assessment of DOACs.  
41  
42  
43  
44  
45

#### 46 *Contributor ship statement*

47  
48 LH, XR, CF designed the study. All authors have contributed substantially to the  
49  
50 interpretation of results. In addition: LH and AB drafted the article; - CF conducted the  
51  
52 statistical analysis; CF, CR, SL, LB, SS, OM, XR provided critical revision of the manuscript for  
53  
54  
55

1  
2  
3 important intellectual content. All authors had full access to all of the data (including  
4  
5 statistical reports and tables) in the study and can take responsibility for the integrity of the  
6  
7 data and the accuracy of the data analysis. All authors approved the version to be published.  
8  
9

### 10 11 12 *Competing interests*

13  
14 Pr. Suissa has participated in advisory board meetings and received research grants from  
15  
16 Bayer, Boehringer Ingelheim, Bristol-Myers-Squibb and Novartis. These activities are  
17  
18 conducted outside this submitted study.  
19

20  
21 All other co-authors have no conflict of interest.  
22  
23

### 24 25 26 *Funding*

27  
28 This research was supported by a 2012 research grant from the Agence Nationale de  
29  
30 Sécurité du Médicament (ANSM).  
31  
32

### 33 34 35 *Data sharing statement*

36  
37 No additional data are available directly from the authors. The datasource of the study is the  
38  
39 French National Health Insurance. Data are available from the Caisse National de l'Assurance  
40  
41 Maladie des Travailleurs Salariés (CNAMTS) for academic research.  
42  
43

### 44 45 46 *Ethics approval*

47  
48 The study was approved by the French National Institute of Data, and by the National  
49  
50 Commission for Data Protection and Liberties (CNIL-France: authorization number:  
51  
52 1637014).  
53  
54

### Acknowledgements

We thank the Caisse National de l'Assurance Maladie des Travailleurs Salariés (CNAMTS) and the Institut des Données de Santé (IDS) for their assistance in obtaining the study database.

We personally thank Ms. Valérie EDEL from the IDS, as well as Mr. Laurent DUCHET and Mr. Medhi GABBAS from the department in charge of the SNIIRAM DATA at CNAM-TS.

We are indebted to Arianne Dorval for proofreading the English manuscript. C Renoux is the recipient of a Chercheur-Boursier Award from the Fonds de la recherche du Québec - santé (FRQ-S). S Suissa is the recipient of the James McGill Chair.

### References

1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation* 2004; **110**(9): 1042-6.
2. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. *International journal of cardiology* 2013; **167**(5): 1807-24.
3. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology* 2012; **14**(10): 1385-413.
4. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology* 2014; **64**(21): e1-76.
5. Jones C, Pollit V, Fitzmaurice D, Cowan C. The management of atrial fibrillation: summary of updated NICE guidance. *BMJ* 2014; **348**: g3655.
6. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *The Canadian journal of cardiology* 2014; **30**(10): 1114-30.
7. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**(2 Suppl): e531S-75S.
8. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Annals of internal medicine* 2007; **146**(12): 857-67.

9. De Caterina R, Husted S, Wallentin L, et al. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. *Thrombosis and haemostasis* 2013; **109**(4): 569-79.
10. Fihn SD, Callahan CM, Martin DC, McDonnell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. *Annals of internal medicine* 1996; **124**(11): 970-9.
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *The New England journal of medicine* 2009; **361**(12): 1139-51.
12. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *The New England journal of medicine* 2011; **365**(10): 883-91.
13. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. *The New England journal of medicine* 2011; **365**(11): 981-92.
14. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014; **383**(9921): 955-62.
15. Potpara TS, Lip GY. Novel oral anticoagulants in non-valvular atrial fibrillation. *Best Pract Res Clin Haematol* 2013; **26**(2): 115-29.
16. Shields AM, Lip GY. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. *J Intern Med* 2015; **278**(1): 1-18.
17. Haute Autorité de Santé. Fibrillation auriculaire non valvulaire - Quelle place pour les anticoagulants oraux non antivitamine K: apixaban (Eliquis®), dabigatran (Pradaxa®) et rivaroxaban (Xarelto®). 2013. [http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-07/fs\\_bum\\_naco\\_v5.pdf](http://www.has-sante.fr/portail/upload/docs/application/pdf/2013-07/fs_bum_naco_v5.pdf).
18. Ferdynus C, Huiart L. [Technical improvement of cohort constitution in administrative health databases: Providing a tool for integration and standardization of data applicable in the French National Health Insurance Database (SNIIRAM)]. *Rev Epidemiol Sante Publique* 2016; **64**(4): 263-9.
19. Bezin J, Duong M, Lassalle R, et al. The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. *Pharmacoepidemiology and drug safety* 2017; **26**(8): 954-62.
20. Martin-Latry K, Begaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can! *Pharmacoepidemiology and drug safety* 2010; **19**(3): 256-65.
21. Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. *Fundamental & clinical pharmacology* 2016; **30**(6): 616-24.
22. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010; **138**(5): 1093-100.
23. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest* 2010; **137**(2): 263-72.
24. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. *Circulation Cardiovascular quality and outcomes* 2012; **5**(5): 615-21.

- 1
- 2
- 3 25. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National Trends in Ambulatory
- 4 Oral Anticoagulant Use. *The American journal of medicine* 2015; **128**(12): 1300-5 e2.
- 5 26. Loo SY, Dell'Aniello S, Huiart L, Renoux C. Trends in the prescription of novel oral
- 6 anticoagulants in UK primary care. *Br J Clin Pharmacol* 2017; **83**(9): 2096-106.
- 7 27. Steinberg BA, Holmes DN, Piccini JP, et al. Early adoption of dabigatran and its dosing
- 8 in US patients with atrial fibrillation: results from the outcomes registry for better informed
- 9 treatment of atrial fibrillation. *Journal of the American Heart Association* 2013; **2**(6):
- 10 e000535.
- 11 28. Sorensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial
- 12 fibrillation patients in 2011: a nationwide study. *BMJ open* 2013; **3**(5).
- 13 29. Lip GY, Laroche C, Dan GA, et al. 'Real-world' antithrombotic treatment in atrial
- 14 fibrillation: The EORP-AF pilot survey. *The American journal of medicine* 2014; **127**(6): 519-29
- 15 e1.
- 16 30. Mochalina N, Joud A, Carlsson M, et al. Antithrombotic therapy in patients with non-
- 17 valvular atrial fibrillation in Southern Sweden: A population-based cohort study. *Thrombosis*
- 18 *research* 2016; **140**: 94-9.
- 19 31. Desai NR, Krumme AA, Schneeweiss S, et al. Patterns of initiation of oral
- 20 anticoagulants in patients with atrial fibrillation- quality and cost implications. *The American*
- 21 *journal of medicine* 2014; **127**(11): 1075-82 e1.
- 22 32. Larsen TB, Potpara T, Dagues N, Proclemer A, Sciarrafia E, Blomstrom-Lundqvist C.
- 23 Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in
- 24 different clinical situations: results of the European Heart Rhythm Association Survey. *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the*
- 25 *working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the*
- 26 *European Society of Cardiology* 2015; **17**(5): 819-24.
- 27 33. Garjon FJ, Azparren A, Vergara I, Azaola B, Loayssa JR. Adoption of new drugs by
- 28 physicians: a survival analysis. *BMC health services research* 2012; **12**: 56.
- 29 34. Opstelten W, van den Donk M, Kuijpers T, Burgers J. New oral anticoagulants for
- 30 nonvalvular atrial fibrillation in the elderly: Limited applicability in primary care. *The*
- 31 *European journal of general practice* 2015; **21**(2): 145-9.
- 32 35. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. *Jama*
- 33 2015; **313**(19): 1950-62.
- 34 36. Wisloff T, Hagen G, Klemp M. Economic evaluation of warfarin, dabigatran,
- 35 rivaroxaban, and apixaban for stroke prevention in atrial fibrillation. *PharmacoEconomics*
- 36 2014; **32**(6): 601-12.
- 37 37. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative
- 38 effectiveness of newly marketed medications: methodological challenges and implications
- 39 for drug development. *Clinical pharmacology and therapeutics* 2011; **90**(6): 777-90.
- 40 38. Agence Nationale de Sécurité du Médicament et des produits de santé. Nouveaux
- 41 anticoagulants oraux Eliquis (apixaban), Pradaxa (dabigatran), Xarelto (rivaroxaban) : mise en
- 42 garde sur les facteurs de risques hémorragiques - Lettre aux professionnels de santé. 2013.
- 43 39. Haute Autorité de Santé. Les anticoagulants oraux antivitamine K restent la référence
- 44 dans la fibrillation auriculaire non valvulaire - Communiqué de presse. 2013.
- 45 40. Haute Autorité de Santé. Point sur l'utilisation des nouveaux anticoagulants oraux -
- 46 Communiqué de Presse. 2013 [cited; Available from: <http://www.has->
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

1  
2  
3 [sante.fr/portail/jcms/c\\_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-](http://sante.fr/portail/jcms/c_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux)  
4 [oraux](http://sante.fr/portail/jcms/c_1700943/fr/point-sur-l-utilisation-des-nouveaux-anticoagulants-oraux)

5 41. Tuppin P, Rudant J, Constantinou P et al. "Value of a national administrative  
6 database to guide public decisions: From the systeme national d'information interregimes de  
7 l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in  
8 France." *Rev Epidemiol Sante Publique* 2017; **65**(Suppl 4): S149-S167.  
9

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 **Figure 1 – Flow-chart describing cohort constitution**  
4  
5  
6

7 **Figure 2 – Time trends in the prescription of anticoagulants in newly treated patients with**  
8  
9 **Atrial Fibrillation between 2011 and 2015 in France (n = 814,446)**  
10

11 (VKA: vitamin K antagonist, DOAC: direct oral anticoagulant)  
12

13  
14 Significant changepoints in trends identified a segmented regression model (a): Dabigatran  
15 reimbursement approval, (b): Rivaroxaban reimbursement approval, (c): and Apixaban  
16 reimbursement approval, (d): Security warning (risks of bleeding hemorrhages) from the  
17 National Health Agency, (e): Downgrade of Dabigatran reimbursement.  
18  
19  
20  
21  
22  
23  
24

25 **Figure 3 – HAS-BLED and CHA2DS2-VASc scores associated with DOAC vs VKA initiation**  
26  
27 **according to year of therapy initiation. Crude Odds Ratio and 95% confidence interval**  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 – Flow-chart describing cohort constitution

180x260mm (300 x 300 DPI)






Figure 2 – Time trends in the prescription of anticoagulants in newly treated patients with Atrial Fibrillation between 2011 and 2015 in France (n = 814,446)

(VKA: vitamin K antagonist, DOAC: direct oral anticoagulant)

Significant change points in trends identified a segmented regression model (a): Dabigatran reimbursement approval, (b): Rivaroxaban reimbursement approval, (c): and Apixaban reimbursement approval, (d): Security warning (risks of bleeding hemorrhages) from the National Health Agency, (e): Downgrade of Dabigatran reimbursement.

164x220mm (300 x 300 DPI)




Figure 3 – HAS-BLED and CHA2DS2-VASc scores associated with DOAC vs VKA initiation according to year of therapy initiation. Crude Odds Ratio and 95% confidence interval

168x150mm (300 x 300 DPI)



**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015)**

*	VKA*	DOACs <sup>†</sup>
	N = 289,430	N = 199,016
<b>Demographic characteristics</b>		
Mean age (sd <sup>§</sup> )	76.1 (11.2)	73.7 (11.3)
Male	49.8%	52.5%
<b>Clinical characteristics<sup>  </sup></b>		
High blood pressure	91.9%	88.7%
Ischemic heart disease	26.3%	16.6%
Heart failure	34.4%	21.6%
Diabetes	21.9%	18.6%
Cancer	16.1%	13.0%
Renal failure	9.7%	2.4%
Liver failure	1.3%	0.7%
Dementia	4.6%	2.7%
History Ischemic stroke	8.5%	6.2%
History of bleeding	5.5%	2.9%
HAS-BLED score, mean (sd)	2.6 (0.9)	2.4 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> score, mean (sd)	3.9 (1.5)	3.4 (1.5)
<b>Other treatment at cohort entry<sup>¶</sup></b>		
Aspirin	45.9%	42.2%
Nonsteroidal anti-inflammatory drugs	13.8%	15.9%
Antiplatelet Agents (other than Aspirin)	14.4%	10.9%
Corticosteroids	13.9%	12.8%
<b>Prescriber of first anticoagulant</b>		
General Practitioner	59.7%	46.7%
<i>Among general practitioners</i>	65.0%	35.0%
Cardiologist	27.7%	43.8%
<i>Among cardiologists</i>	47.9%	52.1%
Other specialist	4.2%	3.8%
Unknown	8.4%	5.6%

Vitamin K agonist; <sup>†</sup> Direct oral anticoagulants; <sup>‡</sup>, p value comparing VKA vs DOACs; <sup>§</sup> sd: standard deviation; <sup>||</sup> defined in the 12 months prior to cohort entry; <sup>¶</sup> defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 2 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation in the Sub-Group of Patients Receiving a Direct Oral Anticoagulant (2011-2015)**

	<b>Dabigatran</b> <b>N = 65,851</b>	<b>Rivaroxaban</b> <b>N = 104,936</b>	<b>Apixaban</b> <b>N = 28,229</b>
<b>Demographic characteristics</b>			
Mean age (sd) <sup>†</sup>	73.7 (11.4)	73.0 (11.3)	76.0 (11.0)
Male	52.3%	53.4%	49.6%
<b>Clinical characteristics<sup>‡</sup></b>			
High blood pressure	88.7%	87.8%	91.8%
Ischemic heart disease	17.9%	15.8%	17.0%
Heart failure	22.8%	19.9%	25.2%
Diabetes	18.6%	18.3%	20.0%
Cancer	14.0%	12.8%	11.3%
Renal failure	2.1%	2.2%	3.8%
Liver failure	0.7%	0.6%	0.6%
Dementia	2.8%	2.6%	2.9%
History of ischemic stroke	7.2%	5.4%	7.1%
History of bleeding	2.7%	2.7%	3.6%
HAS-BLED score, mean (sd)	2.4 (0.9)	2.3 (0.9)	2.5 (0.9)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> , mean (sd)	3.4 (1.5)	3.2 (1.5)	3.6 (1.4)
<b>Other treatments at cohort entry<sup>§</sup></b>			
Aspirin	43.0%	41.4%	43.2%
Nonsteroidal anti-inflammatory drugs	16.6%	16.1%	13.2%
Antiplatelet Agents (other than Aspirin)	11.3%	10.4%	12.1%
Corticosteroids	12.8%	12.8%	12.6%
<b>Prescriber of first anticoagulant</b>			
General Practitioner	47.0%	46.3%	47.5%
Cardiologist	43.1%	44.9%	41.7%
Other specialist	3.7%	3.8%	4.1%
Unknown	6.2%	5.0%	6.7%

\* Direct oral anticoagulants, † Standard deviation, ‡ defined in the 12 months prior to cohort entry, § defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 1** - patients newly treated with an anticoagulant combined with an antiarrhythmic agent or a rate control treatment excluding beta-blockers, within a time window of +/- 30 days

**Table 3 – Multivariate analysis of the determinants associated with DOAC initiation according to year of therapy initiation**

Characteristics at treatment initiation	2011 N = 101,817		2012 N = 110,571		2013 N = 103,594		2014 N = 94,180		2015 N = 78,284	
	Adjusted OR	CI 95%*	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%
<b>Demographic characteristics</b>										
Age										
< 65 years	0.89	0.78 – 1.01	0.93	0.88 – 0.97	1.02	0.98 – 1.06	1.15	1.10 – 1.21	1.08	1.03 – 1.14
65 –74 years	1.0		1.0		1.0		1.0		1.0	
>= 75 years	1.15	1.04 – 1.27	0.98	0.94 – 1.01	0.69	0.67 – 0.71	0.59	0.57 – 0.61	0.65	0.63 – 0.68
Sex (Male)	0.86	0.79 – 0.94	0.97	0.94 – 1.01	1.09	1.06 – 1.13	1.10	1.06 – 1.13	1.08	1.05 – 1.12
<b>Clinical characteristics<sup>†</sup></b>										
High blood pressure	0.87	0.76 – 1.00	0.82	0.78 – 0.86	0.79	0.75 – 0.83	0.78	0.74 – 0.82	0.79	0.74 – 0.84
Ischemic heart disease	0.88	0.79 – 0.97	0.83	0.80 – 0.86	0.76	0.74 – 0.79	0.74	0.72 – 0.77	0.76	0.72 – 0.79
Heart failure	0.60	0.55 – 0.67	0.70	0.68 – 0.72	0.61	0.59 – 0.63	0.59	0.57 – 0.61	0.63	0.60 – 0.65
Diabetes	0.88	0.79 – 0.98	0.89	0.86 – 0.93	0.88	0.85 – 0.91	0.93	0.89 – 0.96	0.92	0.89 – 0.96
Cancer	0.98	0.88 – 1.10	0.96	0.92 – 1.00	0.85	0.81 – 0.88	0.85	0.81 – 0.88	0.84	0.80 – 0.89
Renal failure	0.50	0.39 – 0.63	0.34	0.31 – 0.36	0.23	0.22 – 0.25	0.22	0.20 – 0.23	0.24	0.23 – 0.26
Liver failure	0.59	0.33 – 1.05	0.74	0.63 – 0.88	0.59	0.52 – 0.68	0.58	0.50 – 0.66	0.49	0.41 – 0.58
Dementia	0.96	0.77 – 1.19	0.84	0.77 – 0.92	0.75	0.70 – 0.80	0.81	0.76 – 0.88	0.74	0.68 – 0.81
History of Ischemic Stroke	1.01	0.87 – 1.16	0.99	0.94 – 1.05	0.88	0.84 – 0.93	0.88	0.84 – 0.93	0.92	0.86 – 0.98
History of bleeding	1.28	1.06 – 1.55	0.70	0.64 – 0.76	0.52	0.48 – 0.55	0.52	0.49 – 0.56	0.57	0.53 – 0.61
<b>Prescriber of first anticoagulant</b>										
General Practitioner	1.0		1.0		1.0		1.0		1.0	
Cardiologist	1.30	1.19 – 1.42	2.33	2.25 – 2.41	2.63	2.55 – 2.71	2.57	2.49 – 2.65	2.46	2.37 – 0.56
Other specialists/Unknown	1.72	1.52 – 1.93	1.03	0.97 – 1.08	1.00	0.96 – 1.05	1.03	0.98 – 1.07	1.03	0.98 – 1.08
<b>Other treatments at cohort entry<sup>‡</sup></b>										
Aspirin	1.28	1.18 – 1.42	1.16	1.12 – 1.19	0.98	0.85 – 1.00	0.93	0.90 – 0.95	0.87	0.84 – 0.90
NSAID	1.37	1.24 – 1.52	1.16	1.11 – 1.21	1.18	1.13 – 1.22	1.21	1.17 – 1.27	1.20	1.14 – 1.26
Antiplatelet Agents	1.30	1.15 – 1.46	1.06	1.01 – 1.11	0.85	0.82 – 0.89	0.73	0.70 – 0.76	0.78	0.74 – 0.82
Corticosteroids	0.90	0.79 – 1.02	0.96	0.92 – 1.00	0.93	0.89 – 0.96	0.98	0.94 – 1.02	0.92	0.88 – 0.96
<b>Time of anticoagulant initiation</b>										
1 <sup>st</sup> term of the year	1.0		1.0		1.0		1.0		1.0	
2 <sup>nd</sup> term of the year	1.13	0.96 – 1.32	3.17	2.98 – 3.37	1.00	0.96 – 1.04	1.08	1.04 – 1.13	1.11	1.06 – 1.15
3 <sup>rd</sup> term of the year	2.05	1.77 – 2.37	9.37	8.84 – 9.94	0.93	0.89 – 0.96	1.09	1.05 – 1.14	1.17	1.11 – 1.22
4 <sup>th</sup> term of the year	4.71	4.14 – 5.36	31.06	29.34 – 32.88	0.54	0.52 – 0.56	1.35	1.30 – 1.40	1.39	1.33 – 1.45

\* 95% Confidence interval; † defined in the 12 months prior to cohort entry; ‡ defined in the 3 months prior to cohort entry

Supplemental material – Sensitivity analysis – Cohort 2 - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant therapies

Table 1 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation (2011-2015).

	VKA*	DOACs <sup>†</sup>
	N = 952,565	N = 661,089
<b>Demographic characteristics</b>		
Mean age (sd <sup>§</sup> )	71.7 (15.3)	69.5 (13.8)
Male	48.4%	49.2%
<b>Clinical characteristics<sup>  </sup></b>		
High blood pressure	78.5%	71.3%
Ischemic heart disease	21.0%	11.9%
Heart failure	18.6%	8.8%
Diabetes	19.9%	15.7%
Cancer	16.7%	11.6%
Renal failure	9.3%	1.9%
Liver failure	1.6%	0.6%
Dementia	5.5%	2.4%
History Ischemic stroke	8.6%	5.0%
History of bleeding	6.8%	3.6%
HAS-BLED score, mean (sd)	2.3 (1.1)	2.0 (1.1)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> score, mean (sd)	3.3 (1.7)	2.8 (1.6)
<b>Other treatment at cohort entry<sup>¶</sup></b>		
Aspirin	35.8%	28.9%
Nonsteroidal anti-inflammatory drugs	17.1%	28.4%
Antiplatelet Agents (other than Aspirin)	11.7%	7.4%
Corticosteroids	15.1%	12.7%
<b>Prescriber of first anticoagulant</b>		
General Practitioner	70.7%	54.1%
<i>Among General Practitioners</i>	64.7%	35.3%
Cardiologist	15.6%	21.7%
<i>Among Cardiologists</i>	50.0%	50.0%
Other specialist	5.8%	18.2%
Unknown	7.9%	6.0%

\* Vitamin K agonist; † Direct oral anticoagulants; ‡, p value comparing VKA vs DOACs; § sd: standard deviation; || defined in the 12 months prior to cohort entry; ¶ defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 2** - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant therapies

**Table 2 – Characteristics of Patients and Prescribers at Anticoagulant Treatment Initiation in the Sub-Group of Patients Receiving a Direct Oral Anticoagulant (2011-2015) AC**

	<b>Dabigatran</b> <b>N = 174,423</b>	<b>Rivaroxaban</b> <b>N = 419,780</b>	<b>Apixaban</b> <b>N = 66,886</b>
<b>Demographic characteristics</b>			
Mean age (sd <sup>†</sup> )	71.5 (12.5)	67.8 (14.3)	74.5 (11.8)
Male	49.6%	49.0%	49.4%
<b>Clinical characteristics<sup>‡</sup></b>			
High blood pressure	76.9%	66.9%	84.4%
Ischemic heart disease	14.8%	10.4%	14.0%
Heart failure	11.0%	6.9%	15.3%
Diabetes	16.9%	14.6%	18.8%
Cancer	12.7%	11.3%	10.8%
Renal failure	1.9%	1.7%	3.7%
Liver failure	0.6%	0.6%	0.6%
Dementia	2.6%	2.2%	3.1%
History of ischemic stroke	6.5%	3.9%	8.4%
History of bleeding	3.5%	3.6%	4.0%
HAS-BLED score, mean (sd)	2.2 (1.0)	1.9 (1.1)	2.4 (1.0)
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> , mean (sd)	3.0 (1.6)	2.6 (1.6)	3.4 (1.5)
<b>Other treatments at cohort entry<sup>§</sup></b>			
Aspirin	32.8%	25.9%	37.6%
Nonsteroidal anti-inflammatory drugs	28.3%	29.8%	19.4%
Antiplatelet Agents (other than Aspirin)	8.7%	6.4%	10.1%
Corticosteroids	11.9%	13.1%	11.7%
<b>Prescriber of first anticoagulant</b>			
General Practitioner	48.2%	56.9%	51.4%
Cardiologist	24.1%	19.6%	29.2%
Other specialist	20.9%	18.0%	12.0%
Unknown	6.8%	5.5%	7.4%

\* *Direct oral anticoagulants*, † Standard deviation, ‡ defined in the 12 months prior to cohort entry, § defined in the 3 months prior to cohort entry

**Supplemental material – Sensitivity analysis – Cohort 2** - Cohort all patients newly treated with an anticoagulant therapy regardless of other potential concomitant therapies

**Table 3 – Multivariate analysis of the determinants associated with DOAC initiation according to year of therapy initiation.**

Characteristics at treatment initiation	2011 N = 319*,372		2012 N = 353,242		2013 N = 327,150		2014 N = 311,352		2015 N =275,538	
	Adjusted OR	CI 95%*	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%	Adjusted OR	CI 95%
<b>Demographic characteristics</b>										
Age										
< 65 years	0.57	0.56 – 0.59	0.63	0.62 – 0.64	0.74	0.72 – 0.76	0.81	0.79 – 0.82	0.81	0.79 – 0.83
65 –74 years	1.0		1.0		1.0		1.0		1.0	
>= 75 years	0.56	0.55 – 0.58	0.76	0.75 – 0.78	0.69	0.68 – 0.70	0.59	0.58 – 0.60	0.66	0.65 – 0.67
Sex (Male)	0.86	0.84 – 0.88	0.98	0.96 – 0.99	1.09	1.07 – 1.11	1.08	1.06 – 1.09	1.06	1.04 – 1.08
<b>Clinical characteristics<sup>†</sup></b>										
High blood pressure	0.76	0.74 – 0.78	0.90	0.88 – 0.92	0.95	0.93 – 0.97	0.89	0.87 – 0.91	0.87	0.85 – 0.89
Ischemic heart disease	0.78	0.76 – 0.81	0.81	0.79 – 0.83	0.76	0.75 – 0.78	0.74	0.72 – 0.76	0.77	0.75 – 0.80
Heart failure	0.15	0.14 – 0.16	0.56	0.54 – 0.57	0.63	0.62 – 0.64	0.58	0.56 – 0.59	0.64	0.63 – 0.66
Diabetes	0.89	0.86 – 0.92	0.90	0.88 – 0.92	0.89	0.87 – 0.91	0.89	0.87 – 0.91	0.91	0.89 – 0.93
Cancer	0.71	0.69 – 0.73	0.81	0.79 – 0.83	0.75	0.73 – 0.76	0.73	0.72 – 0.75	0.70	0.68 – 0.72
Renal failure	0.29	0.27 – 0.32	0.30	0.29 – 0.32	0.23	0.22 – 0.24	0.22	0.21 – 0.23	0.26	0.25 – 0.27
Liver failure	0.50	0.44 – 0.57	0.50	0.46 – 0.55	0.47	0.43 – 0.50	0.43	0.40 – 0.47	0.40	0.37 – 0.44
Dementia	0.29	0.26 – 0.31	0.56	0.54 – 0.59	0.61	0.59 – 0.63	0.60	0.58 – 0.63	0.63	0.60 – 0.66
History of Ischemic Stroke	0.24	0.22 – 0.26	0.66	0.64 – 0.68	0.76	0.74 – 0.78	0.74	0.72 – 0.76	0.81	0.78 – 0.84
History of bleeding	1.00	0.95 – 1.05	0.70	0.68 – 0.73	0.54	0.52 – 0.56	0.53	0.51 – 0.55	0.54	0.52 – 0.56
<b>Prescriber of first anticoagulant</b>										
General Practitioner	1.0		1.0		1.0		1.0		1.0	
Cardiologist	0.26	0.25 – 0.28	1.91	1.87 – 1.95	2.86	2.80 – 2.92	2.78	2.72 – 2.84	2.67	2.60 – 2.73
Other specialists/Unknown	7.01	6.85 – 7.18	3.76	3.69 – 3.84	1.83	1.79 – 1.87	1.79	1.75 – 1.82	1.55	1.51 – 1.58
<b>Other treatments at cohort entry<sup>‡</sup></b>										
Aspirin	0.71	0.69 – 0.73	1.00	0.98 – 1.02	0.98	0.96 – 1.00	0.91	0.90 – 0.93	0.87	0.85 – 0.88
NSAID	2.77	2.71 – 2.83	1.93	1.90 – 1.97	1.57	1.54 – 1.60	1.56	1.53 – 1.59	1.57	1.53 – 1.60
Antiplatelet Agents	0.64	0.61 – 0.68	0.94	0.91 – 0.97	0.83	0.81 – 0.85	0.75	0.72 – 0.77	0.76	0.73 – 0.78
Corticosteroids	0.60	0.58 – 0.62	0.70	0.68 – 0.72	0.79	0.77 – 0.80	0.84	0.82 – 0.86	0.87	0.85 – 0.89
<b>Time of anticoagulant initiation</b>										
1 <sup>st</sup> term of the year	1.0		1.0		1.0		1.0		1.0	
2 <sup>nd</sup> term of the year	1.02	0.99 – 1.05	1.35	1.32 – 1.38	1.05	1.03 – 1.07	1.12	1.10 – 1.14	1.10	1.08 – 1.13
3 <sup>rd</sup> term of the year	0.81	0.78 – 0.83	2.22	2.17 – 2.28	0.96	0.94 – 0.98	1.09	1.07 – 1.12	1.12	1.10 – 1.15
4 <sup>th</sup> term of the year	1.32	1.29 – 1.37	5.92	5.79 – 6.05	0.69	0.68 – 0.70	1.38	1.35 – 1.41	1.31	1.28 – 1.34

\* 95% Confidence interval; † defined in the 12 months prior to cohort entry; ‡ defined in the 3 months prior to cohort entry



Supplementary table – Sources of codes used for the definition of covariates

Covariates at cohort entry	Definitions			
	Drug claims	Hospital discharge diagnoses (main or associated)	Hospital Inpatient procedures	Long duration disease codes
High blood pressure	X	X		X
Ischemic heart disease		X		
Heart failure	X	X		X
Diabetes	X	X		X
Cancer	X	X		X
Renal failure		X	X	X
Liver failure		X		X
Dementia	X	X		X
History Ischemic stroke		X		X
History of bleeding	X	X		
HAS-BLED score	X	X	X	X
CHA <sub>2</sub> DS <sub>2</sub> - VASc <sub>2</sub> score	X	X		X
Aspirin	X			
Nonsteroidal anti-inflammatory drugs	X			
Antiplatelet Agents (other than Aspirin)	X			
Corticosteroids	X			

**STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology\***  
**Checklist for cohort, case-control, and cross-sectional studies (combined)**

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5-6
Objectives	3	State specific objectives, including any pre-specified hypotheses	6
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	7-8
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	6
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	8
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8
Bias	9	Describe any efforts to address potential sources of bias	9
Study size	10	Explain how the study size was arrived at	Database study – NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	9
		(c) Explain how missing data were addressed	Administrative database study – no missing variable

		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Only variable at cohort entry were used
		(e) Describe any sensitivity analyses	9
<b>Results</b>			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	11 and figure 1
		(c) Consider use of a flow diagram	Fig 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Table 1
		(b) Indicate number of participants with missing data for each variable of interest	NA – admin database study – no missing variables
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Variables only at cohort entry
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Table 2
		(b) Report category boundaries when continuous variables were categorized	Table 1
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Supplementary table
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15
Generalisability	21	Discuss the generalisability (external validity) of the study results	12
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on	14

1  
2  
3  
4 which the present article is based  
5

6 \*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

7 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE  
8 checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
9 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

For peer review only